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This sttrly was designed to detennine the changes in plasma 
lipoprotein levels (cholesterol, triglyceride, cholesterol ester and 
phospholipids) following the infusion of an intravenous fat anulsion 
(Liposyn 10%, Aboott Laooratories, Chicago) and to identify the 
cxxnpositional changes in the lipoprotein fractions (VI.DL, IDL, and 
HDL). 
Fbur adults patients (three females, ooe male), ranging in age 
fran 38-79 years were admitted to this sttrly. 'lhese patients were 
referred to the Clinical Nutrition Unit as they presented with G.I./ 
pancreatic malfunction and /or malnutrition requiring total 
parenteral nutrition (TPN) su~rt. Each patient served as his/her 
own rontrol. All patients recieved a fat free Tm solution 24 oours 
before the fat anulsion was injected. On the experinental days the 
fat anulsion was adm.instrated roncurrently with TPN solution at the 
-iii-
rate of 1 ml/min during the first 15 to 20 minutes and then 
increased to 125 ml/ hr. After the fat infusion, the patients 
resuned the fat free TPN solution. 
The lip:>protein fractions were isolated by density 
fractionation and analyzed by thin layer chranatrography to 
detennine a:xnpositional changes. Statistical analyses were ci>ne on 
blood sarcples drawn at preinfusion, during infusion (1 and 4 oours) 
and p:>stinfusion (h::>ur 18) for each of the bJo experllleltal days. 
All p:>stinfusion (oour 18) levels of plasma lipids and their 
subfractions returned to their baseline levels. wtx>le plasma 
fractions showed the rrost changes four h::>urs after the start of the 
infusion. Triglycerides increased, at 1 and 4 hours p:>St Lip:>syn 
adminstration, in the VIDL fraction; at 4 hours p:>stinfusion, in the 
HDL fraction; and 1 and 4 hours p:>stinfusion in whole plasma. 'lhese 
result are oontrary to research studies with another fat errulsion 
(Intralipid) which have sl:riwn an elevation of free coolesterol and 
phospholipid; the majority of these changes occurring in the IDL 
fraction. The difference in results may be due to a dilution of the 
plasma volurre caused by the the infusion of the fat emulsion. ~ 
a oorrection was made for this, an increase in plasma cholesterol 
and phospholipid was evident; with the greatest percent increase 
occuring in the IDL fraction. 
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IN'IRODUCTION 
For the past fifty years, a major ooncem of rredical science 
has been how to best supply nutrients to an ill or trauna patient in 
order to provide them with substrates necessary for analx>lism and 
repair of oody tissues. Dtrlrick (1968) successfully derconstrated 
that beagle puwies ~uld grCM when intravenously fed a solution of 
gluoose, amino acids, and vitamins. The basic fonnulation has been 
altered slighlty over the years. The nutrient solution oontains 
minerals and fat as ,;,.,iell as gluoose, anino acids, and vitamins. The 
percent a::niposition of lx>th the fat and the gluoose can be altered 
to rreet specific patient needs. 
T~ soope for use for total parenteral nutrition (TPN) is 
broad. It can be used for patients with gastrointestional and 
accessory organ disorders as ,;,.,iell as for those preparing for or 
reoovering frcm surgery, cxxrplicated trauna such as rums, or other 
oonditions like a:ma and cancer. TPN has proven itself to be a 
"life giving" iredical tool with the risks and cx:mplications of its 
use ,;,.,iell defined (Dtrlrick et al, 1969: Dtrlrick et al, 1980: Wilm:>re 
et al,1973: Ali:ot,1979). 
With the question of effectiveness settled, the issue arises as 
to other applications for total parenteral nutrition. A p:>5sible 
area of investigation is the use of Tm as a fonn of dietary 
manipulation in disease oonditions such as atherosclerosis. 
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Research has oocurrented that a high oonsurrption of dietary 
cholesterol will cause an elevation in plasma cholesterol 
(Ma;ill,1976), and that this increase occurs in the IDL fraction of 
the lipoproteins ( 'Ihanpson et al, 19 76; Shepherd et al, 19 80 ) • Based 
on epidemiological evidence, it appears that high HDL (high density 
lipoproteins) levels a:xnbined with low LDL ( low density 
lipoproteins) is protective against atherosclerosis while the 
reverse relationship is associated with a greater risk of developing 
the disease (Barr et al, 1951; Miller & Miller, 1975; Gordon et al, 
19 77; Castelli et al , 19 77 ) • Furthermore , elevated HDL levels have 
been oocurrented in group:; who ma.y have a decreased incidence of 
cardiovascular disease; narrely ma.rathon runners (Hartung et al, 
19 80 ) , \l,1CJTeI1 (Gordon, 19 77) , and individuals who oonsurre rroderate 
am::>unts of alcohol (Castelli,1977). 
CUrrently it is thought that HDL precursors (bilayer larrellar 
fragnents or discodiol larrellar aggregates, Figure 3) ma.y be dervied 
fran chylanicron surface a:>nEX)llents following the netabolic 
hydrolysis of its triglyceride oore (Small & Tall,1978). 'lbese 
precusors acquire apoprotein A-I fran circulating s:p1erical HDL and 
thereby provide the substrates for the lecithin: cholesterol 
acyltransferase reaction (ICM'). This enzyire catalyzes the reaction 
of cholesterol and lecithin to cholesterol ester and lysolecithin. 
The cholesterol found en the surface of the precursors is esterified. 
and rroves to the interior of the particle, fonning a spherical HDL. 
Theoretically this reaction can oontinue m1til the lecithin suwly 
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on the surface of the precursors is exhausted. · The high density 
li!X)proteins that have cb1ated their ap:>protein A-I are rYJw unstable 
and may fuse with other li!X)proteins. If this fusion occurs with a 
chylanicron it may be cleared by the liver, thereby carrying with it 
the cholesterol ester. 
By engineering the cxxrp::>sition of a chylanicron so that it 
oontains little cholesterol and a great deal of phospholipid, it may 
be !X)SSible to establish a chemical gradient whereby the cholesterol 
is drawn to the surface of the HDL precursor where the action of 
I£AT may esterify it. Such an altered "chylanicron" is Li!X)syn, a 
10% fat emulsion. It oontains a rich source of phospholipid and 
minimal cholesterol (less than O .5% nostly fran the egg phosphatide 
emulsifier). It has been oocurrented that fat emulsions are 
rretal:x>lized by the l:ody in a manner similar to chylanicrons 
(Ha.llberg,1965). It has been shown in animals and hurcans that an 
infusion of a fat emulsion will liberate cholesterol fran the 
tissues causing a rise in plasma cholesterol (Friedman & Byers, 
1956; Friedman, 1957; Byers,1958; Th::lrpson et al, 1975; Koga et al, 
19 7 4; Miyahara et al, 19 79 ; Breckenridge et al, 19 79 ) • A rich source 
of phospholipid fran the fat emulsion and cholesterol fran the 
tissues may be two factors that contribute to the formation of 
spherical HDL, thereby increasing the level of circulating. HDL. '!be 
exact relationship between HDL, plasma cholesterol and 
atherosclerosis is not well understocxl. 
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This dissertation will examine the effect an infusion of an 
intravenous fat emulsion in oombination with total parenteral 
nutrition on plasma lipoproteins of very low density lipoproteins 
(VIDL), low density lipoproteins (IDL) and high density lipoproteins 
(:HDL) in patients who can not absorb nutrients through their 
gastrointestional tracts. Changes in the chanical cxxnposition of 
each of these lipoprotein classes will be examined. This study can 
only investigate the changes in the lipoprotein fractions. Further 
studies will have to be ronducted to determine if a fat emulsion in 
oombination with total parenteral nutrition can increase HDL levels 
which in turn may play a role in the treatrrent of atherosclerosis. 
REVIEW OF LITERATURE 
'Ibtal parenteral nutr~~ ,.,,,~ recognized rrethod 
for supporting a patient who can not obtain nutrients through the 
gastrointestional tract (Al:::ott,1976). It is designed to rreet the 
"resting energy needs of these patients in order to provide the 
substrates needed for the synthesis of new lean l:x:xiy tissues" 
(Kinney, 1980). 'lbeoretically excess calories will result in 
lii;x:,genesis. 
The roncept of TPN as a rreans of "feeding" patients was first 
proved practical by Du:irick ( 19 68) whose research paved the way for 
wide clinical applications of the therapy now generally accepted for 
its proven l::a'lefits. Fbr the adult patient, a catheter is inserted 
into the suoclavian vein and directed toward the superior vena cava. 
The gastrointestional tract is bypassed, with the nutrients 
provided to the liver mainly via the hepatic artery rather than the 
ix>rtal vein. 
The clinical indications for 'lPN can be divided into four major 
categories; "p:ttients who can not eat (intestinal oootructions); 
patients who can not eat enough (rums and/or trauma); patients who 
should not eat (pre and/or !X)St GI surgery); and patients who will 
not eat enough (adjunctive radio- or cheno- therapy for cancer)" 
(Dtrlrick and Ruberg, 1971; Ab:>tt,1976). 
Patients receiving total parenteral nutrition must be carefully 
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rronitored. Poss.r le risks such as catheter insertion difficulties, 
catheter related· fections, hyperosarolarity leading to dehydration 
and a::xna, electrol e imbalances and nutrient deficiencies 
necessitate clinic alertness for their prevention and to enhance 
the usefulness of this treatment ~thod (Al:x>tt,1976). 
In order to benefit a patient, parenteral as -well as enteral 
nutrition soould provide an adequate, -well balanced diet inclu:ling 
all nutrients. 'Ibtal parenteral nutrition provides adequate energy 
in the form of gluCX>Se and amino acids suwlertEnted with vitamins 
and minerals. The inclusion of an adequate am:mnt of fat 
(triglyceride) is oonsidered essential for optimal growth and -weight 
gain in animals and hurrans (Holrnan,1976). Until recently, 
triglycerides in the form of a fat emulsion had been exclu:led fran 
TPN solutions in this oountry due to restrictions .imposed by the 
Food and Drug .Administration (FDA). 
During the past fifty years, much difficulty has been 
experienced in finding a suitable way of giving fat parenterally. 
Tre first intravenous fat emulsion of 3% castor oil with an egg 
lecithin emulsifier (Yanol) was developed in the 19201 s by NatErra 
and Janakawa (Tlx:mpson, 1974). The castor oil cc:np:>nent of Yanol 
produced chills and fever (arong other side effects) in patients and 
the project was abandoned. During World War II, the use of an 
intravenous fat emulsion was once again reviewed. Hc:wever, it was 
not tmtil the early 19501 s that Lipcmul, a 10% cottonssed oil 
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emulsion, was int uced. Patients recieving long tenn 
administration of L'panul experienced an overloading syndrcxne. 
(Patients with over oading syndrcxne experienced anorexia, fever, 
headache, at:rlanina pain, nausa, vaniting, and sore throat. They 
showed signs of impaired liver function, anemia, thranb:>cytopenia 
and at times hepatosplenaregaly, si;x,ntanous bleeding and delayed 
blood clotting. The exact nature of this syndrcxne remains 
unexplained. It d:>es not appear to be due to an accumulation of 
lipids in the blood circulation (~g, 1976). Sane believe the 
emulsifier damaged red blood cell rrembranes causing cell 
aggregation. In experilrental animals, the heavy aggregation of red 
blood cells and platelets damage liver, kidney, and lungs (Wilm:>re 
etal 1973).) Due to this adverse effect, Lipanul was withdrawn fran 
the market (Ttunpson, 19 7 4) • In the early 19 60 's, a safe and 
effective fat emulsion was developed by Arvid Wretlind of Karolinska 
Institute and the Vitrum Canpany Stockholm, Sweden). In 1964, 
Intralipid, a 10% soybean oil emulsion, apparently free of side 
effects was made a:mnerically available in Europe (Schuberth, 1961; 
F.dgreen et al, 19 64) • This product was cleared for use in this 
oountry by the FDA in 1974. Since then,several Arrerican carpanies 
have been working to produce a a:xnparable fat emulsion. One of 
these products, recently approved by the Fbod and Drug 
.Adminstration, is Lii;x,syn, a 10% safflower oil emulsion. 
\ 
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ADVANTAGES OF T EMUISIONS. Fat emulsion can be used as an 
energy source to +ve nitrogen balance as fats are a ooncentrated 
source of kcalories (Grotte et al,1976). '!he metaoolism of one gram 
of fat provides 9.1 kcalories cxxrpared to 3.4 kcal provided by the 
metaoolism of one gram of glUC'OSe. This means that fat emulsions 
can furnish a greater number of calories in a smaller volure of 
fluid as a:xnpared to glucose solutions. It has been reccmrended 
that b.u grams of fat (in the fonn of Intralipid) per kilogram be 
given to rover ooth the energy and fat requiments in adults. In 
order to obtain the desired energy supply of 30 kcalories per 
kilogram in adults, approximately b.u grarrE caroohydrate (glUC'OSe) 
and one gram of cm1ino acids per kilogram are required in addition to 
the fat emulsion. 
A limitation of total parenteral nutrition has been the 
developrent of essential fatty acid deficiencies (EFAD) in patients 
oot recieving a fat emulsion. A{:proximately, 0.1 gram of linoleic 
acid per kilogram per day is required in the adult patient recieving 
TPN to prevent symptans of essential fatty acid deficiency. '!he 
arrount can be obtained in a 500 ml infusion of Intralipid or Liposyn 
('I'lxlr'p5on,1974; Holrnan,1976; Jeejeebmy et al, 1978). 
Aoother advantage of fat emulsion is its isotonicity. '!he 
OSilDlality of Intalipid is 280 milliosnols, cxxrparable to that of 
blood, so the emulsion may be infused into a peripheral vein without 
fear of altering the OSilDtic pressure of the blood (Hallberg,1965; 
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Grotte et al, 19 76) 
ADVERSE Ef'F'ECI'S OF ~ EMUISIONS. With sane of the previously 
available fat emulsions (Lip:rnul), patients experienced febrile 
response, headache, a mild to rroderate anemia, a slight decrease in 
blood platelets and thranl:x>cytes as -well as soortened blood 
ooagula tion tilre ( 'l'lllnpson, 19 7 4 ) . 'lllese responses have not reen 
otserved in patients recieving either Intralipid or Lip:;yn. No 
significant changes in sennn bilirubin, alkaline phosphatase or 
prothranbin tilre have reen reported using either product 
(Jeejeebooy,1976; Rapp et al, 1979). 
Greene and associates ( 19 76) otserved that pul.rronary rrembrane 
diffusing capacity was significantly decreased in nonnal volunteers 
recieving 500 ml of 10 % Intralipid over four oours. In 'I.Ork with 
burned patients, Wil.Irore (1973) was unable to find any changes 
in pul.rronary diffusing capacity follCYwing an Intralipid infusion. 
Further 'I.Ork in this area is indicated. 
Several researchers have reported the deposition of brown 
pigrrent in . the Kupffer cells of the liver in cbgs and hunan subjects 
given Lip:rnul ('lb:xrpson, 1974; Freund et al, 1975). !))g's, in 
response to the pigrrent, fonn microgranulanas <XX1sisting of 
macrophages, lynphocytes, plasma cells , neutrophils and 
esosiniphils. 'Ille pigrrent and microgranulana fonnation has reen 
otserved in animals and patients recieving Intralipid; tnwever the 
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Intralipid infusion produces fewer changes than other fat emulsions. 
The significance of the fat pigirent deposition is not kno.,,,n. 
Based on these adverse effects, it is recanrended that patients 
with amonnal fat rreta1:x>lism, severe 1i ver disease or pulrronary 
disease not be given intravenous fat emulsion (Tl'olpson, 1974; Meng, 
1974). 
CDMR'.)S!TION F ThT EMUISIONS. Ccrmerically available fat 
emulsions are oil-in-water emulsions with the particle size ranging 
in diarreter fran 100 to 800 nm, similar to the size of chylanicrons. 
Fat emulsions are a::n,posed of three phases; an oil phase, a 
surface phase and the emulsifier. '1'he oil is either safflCMer or 
soybean oil stabilized with purified egg :phospholipids. Glycerol, 
2.5%, is added to make the solution isotonic with the blood. A 
small arrount of sodium hydroxide is added to adjust the pH to 
approx.i.rnately 8.0. 
CliARACTERISTICS OF UroPROI'ErnS. Lipids (cholesterol, 
triglyceride, fatty acid, phospholipid) are insoluble in an aqueous 
rredium. In the lx>dy, the major plasma lipids cb not circulate 
freely. 'Ibey are associated with specific proteins called 
apoproteins forming cx:mplex nnieties; lipoproteins. 
Lipoproteins vary in their particle size as well as their lipid 
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and ap:>protein oontent. They can be classified by their flotation 
densities in the ultracentrifuge or by their electrophoretic 
nobilities. Lip:>proteins isolated fran plasma appear as 
quasi-spherical structures when seen under the electron microscope. 
Physical studies reveal that triglyceride and cholesterol esters 
form the oore of such spheres while the ap::>proteins are associated 
with the surface (Redgrave, 1970). 'lhus, lip:>proteins are anulsion 
or microemulsion of triglycerides and cholesterol esters in which 
the "anulsifiers" are phospholipids, free cholesterol and 
ap::>proteins. The lip:>proteins form a dynamic system for exchange 
and net transfer of protein and lipid. 
LIPID Mm'AIDLISM. Chylanicrons are fornro in the intestine, 
usually oontain small arcounts of cholesterol, J;XlOSpholipids and 
atout 95% or nore triglyceride. '!be ingested fat is cnrlely 
anulsified in the stanach, and ejected into the duodenum where 
pancreatic lipase hydrolyzes the triglyceride to free fatty acids 
and nono and di- glycerides. 'lbese products of lip:>lysis along with 
cholesterol and sare lysophosphotides are made soluble by bile salts 
and translocated to the intestinal brush oorder where they are 
atsorbed into the mucosal cell. Once inside, the lipids are 
re-esterified with fatty acids to form triglycerides, lecithin, and 
cholesterol esters. 'Ihe triglycerides are re-anulsified with 
phospholipids and specific ap::>proteins (ap::>proteins A, A-N, & B) to 
form nascent (newly fonred) dlylanicrons. '!be oore of the 
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chylanicron contains triglyceride, cholesterol ester, and sore free 
I 
cholesterol stabilized by a rrono-f!Dlecular surface film of 
phospholipid, a:p::>protein, and sane cholesterol (Redgrave,1970). '!he 
chylanicrons cnntain roughly 95% triglyceride by weight and range 
fran 100 to 500 nm in dianeter (Biennan, 1976). 'Ihese particles 
leave the al:sorptive cell by exocytosis transverse the intracellular 
space and enter the lyrrphatic system. Fran the peripheral lacteals, 
the chylanicrons pass through the nesenteric, lynphatic, and 
thoracic duct and enter the superior vena cava to be eventually 
trans:p::>rted to the peripheral tissues. 'Ihe CXXllpOSition of the 
chylanicrons are cnntinualJy changing after they leave the cell and 
especially after entering the plasma {Redgrave, 1970; Havel, 1973; 
Biennan, 1976). 
The clearance of chylanicrons fran the blood is rapid. In man, 
the half time disappearance is under one mur {French, 19 5 7) • '!he 
clearance of the chylanicrons is dependent on the ability of a 
tissue to incoq:orate the fatty acids and the activity of enoothial 
li:p::>protein lipase. '!he enzyrre is located in the walls of blood 
capillaries, as well as in extracts of heart, adi:p::>se tissue, 
spleen, lung, renal nedulla, aorta and diaphram {Desnul, 1963; 
Fielding, 19 77) • Both phospholipids and a:p::>protein C-II in 
chylanicron and VIDL are required en-factors for li:p::>protein lipase 
activity. 'Ihe enzyrre selectively hydrolyzes the triglyceride cnre 
of the chylanicron while the li:p::>protein is attached to the enzyrre 
on the endothelium. '!he triglyceride is progressively hydrolyzed to 
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a diglyceride to a rronoglyceride and finally to free fatty acid and 
sane glycerol (Fielding & Havel, 1979). 'll1e fatty acid may return 
to the circulation or enter various local tissues where it may be 
utilized as energy or re-synthesized into triglycerides in fat or 
mU5cle cells utilizing the glycerol suwlies fran the glucose of the 
cell. 
'As the triglyceride is rennved, the chylanicrons shrinks and 
maintains spherical ronformation by losing phospholipid, apoproteins 
A-I and C fran its surface (Mj¢s et al, 1975; Tall & Small, 1978). 
Chylanicron phospholipid appears to give rise to vesicles which are 
probably incorporated into preexisting HDL. 'll1e apoproteins are 
rapidly transferred to the plasma HDL fraction and rontribute to the 
formation of discodial HDL (HDL precusors) (Havel, 1973; Cox, 1978; 
Tall & Small, 1978). Chylanicron isolated fran intestinal lymph 
before entering the circulation rontain appreciable annunts of 
A-apoproteins (Glickman, 1978). Once in the circulation, the 
apoprotein A is lost. Cox ( 19 79 ) and Tall ( 19 79 ) have denonstrated 
a transfer of A-I as well as i;nospholipid into HDL while the nascent 
chylanicrons take up the <XlTlplerent of apoprotein C polypeptides 
oonated fran HDL ( Cox et al, 19 79 ; Tall etal, 19 79 ) • 'Ibis leaves a 
chylanicron ramant rontaining cholesterol, cholesterol ester, sare 
residual triglyceride, apoprotein B and other apoproteins. 'll1e 
rermant acquires apo E (Sherrill et al,1980; Quarfordt et al,1981) 
and is taken up by the liver where the cholesterol ester of the 
rermants are hydrolyzed and the residual triglyceride rretal:x>lized 
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(Redgrave, 19 70) • In this manner, the chylomicron surface cx:mp:ments 
l::eccJre important sources of plasma HDL (see Figure 1). 
DIETAR~- TG 
NASCENT 
CHYLOMICRON 
? 
1-'igure 1. I~tabolic fate of dlylanicrcns. (~B, apop.rotein B; 
APO-C, ap:,protein C; HDL, high d€51sity lipoprotein; TG, triglyceride; 
C, cholesterol and dlolesterol ester.) (Mayes,1976, pg 306) Used 
by permi.ssicn of the publisher. 
\ 
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Very low density lipoprotein (VIDL) produced by the liver, is 
another source of plasma triglycerides. VIDL transports 
triglyceride £ran the liver to the extrahepatic tissues. The liver 
utilizes free fatty acids in the plasma or fatty acids synthesized 
de novo £ran carbohydrates or alcohol to fonn triglycerides. 
Ap:>protein B (essential ai:oprotein for chylanicrons and VIDL) is 
synthesized by the ril:::sanes in the rough encbplasmic reticult.m and 
incori:orated into the lipoprotein in the srrooth encbplasmic 
reticulum which is the main site of synthesis of triglyceride, 
phospholipids, and cholesterol (Schaefer et al, 1978). VIDL is 
secreted by the hepatic parenchymal cells into the space of Disse 
and then into the hepatic sinusoids. Once in the plasma, a similar 
trans£ er of surf ace lipids and apoproteins appears to occur as 
described for the chylanicrons (Havel et al, 1973; Mj0s et al, 
1975). 'Ihe lipoprotein lipase hydrolyzes the triglyceride fran the 
oore of the VIDL particle to free fatty acid and glycerol which 
tecores available to the peripheral tissues. 'Ihe VIDL particle 
minus the triglyceride is oonverted to an intennediate density 
lipoprotein (IDL). Poospholipid, apoproteins A-I, A-II, E, and C 
polypeptides are rerroved £ran the IDL and are rrost likely 
transferred to HDL (Chajek, 1978; Havel, 1973). In this way, 
intennediate low density lipoprotein is fonned into low density 
lipoproteins (IDL). Only one IDL particle is fonned for each VIDl 
particle ( see Figure 2) • 
NASCENT 
VLOL 
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~LOl 
ANAL DESTRUCTION IN GLYCEROL 
EXTRAHE,.,.TIC TISSUES, 
e9 , LYMPHOCYTES, 
FIBROBLASTS 
Figure 2. M:tal:::x::,lic fate of very la,; density lipouroteins (VIDL) . 
(IDL, inte:rnediate density lipoprotein; I.DL, la,; da1sity lipoprotein.) 
(Mayes, 1976, pg 306) · Used by pennissicn of the publisher. 
-17-
LDL is a sm3.ll particle ( 22 nm in diarreter) rontaining 
phospholipid, ap:,protein Band large arrounts of cholesterol (free 
and esterified). In nonnal man, LDL does not appear to re secreted 
but rather fonred fran the :rretal:x)lism of VIDL and p:,ssibly 
chylcmicrons. In other species, LDL may re directly secreted fran 
the liver. Until recently, the liver was ronsidered the major site 
of LDL renoval fran the circulation in man. 'ltere is growing 
evidence that fibroblasts and lymphocytes may degrade LDL in 
extrahepatic tissues by binding LDL to specific cell surface; LDL 
receptor sites (Brown & Goldstein, 1975; 1976; 1979). The 
LDL-receptor CD1I1plex fonI\S a roated vesicule which fuses with a 
primary lysosare to form a secondary lysosare. '!he cholesterol 
ester of the LDL is hydrolyzed by lysosanal cholesterol esterase 
yielding free cholesterol which regulates cellular cholesterol 
:rretal:x)lism. 'lhese specific LDL receptors may re present in a 
variety of tissue such as arterial srrooth muscles. IDL recares the 
primary source of cholesterol to the peripherial tissues (Brown & 
Goldstein, 1979). The rorrelation of high IDL levels to 
atheroscelosis is well oocurrented. 
High density liIX)proteins (HDL) are smaller liIX)protein 
aggreates ( 10 nm in diarreter) • Hman HDL contains by weight 90 % of 
the protein as afX>protein A (A-I and A-II). Atoprotein A-I is 70% 
of the total protein while A-II is 20%. The remaining 10% is 
a::xrq_:x:>sed of C and E IX)lypeptides. Unlike circulating HDL, nascent 
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HDL fran the intestine rontains oqly ap:,protein A. ~protein C 
seems to be synthesized in the liver and transfered to intestinal 
HDL precusors when it enters the plasma (Havel, 1973; 
Fielding, 19 77) • 
HDL or its precursors are secreted by ooth the liver and the 
intestine (Tall and Sma.11, 1979). Nascent HDL appears to be 
secreted into the plasma or lymph as a discodial rnospholipid 
bilayer rontaining free cholesterol, phospholipids, and ap:>proteins 
A-I, A- II, and E ( Hanil i tion , 19 76 ) • The ap:,proteins surround the 
hydrophobic sections of the phosp:>lipids to render the entire 
canplex soluble. 'Ibis discodial HDL particle provides the 
su.1::strates for the lecithin: cholesterol acyltransferase (ICAT) 
reaction (Glanset, 1970; 1977). HDL precursors may also be derived 
fran the surface CDTipOnents of triglyceride-rich lip:>proteins like 
chylanicrons (Figure 3). As nentioned earlier the action of 
lip:>protein lipases hydrolyzes the triglyceride causing the 
chylanicrons to shrink. The "extra" surface CDTipOnents form lipid 
bilayer folds which project fran the chylanicrons. &me! of the 
bilayer may be ronverted to disks by the associations with 
apoproteins A or C. ~ver rrost of the surface a::mes off as 
m1stable bilayer sheets which seal to fonn vesicles. The 
circulating HDL p:>01 may oonate A-I apoprotein to the sheets, 
vesicles, and fold5 which in turn becxxne good su.1::strates for the 
IC.AT reaction. Hanilition (1976) prop:>sed that IC.AT and p:,ssibly 
the IC.AT activator ap:>protein, A-I, bind to the discodial HDL. 
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Catalysis by I.CA[' a:mverts the surface phospoolipid (lecithin} and 
free cholesterol into cholesterol ester and lysolecithin. The 
apolar cholesterol ester partitions itself into the interior oily 
phase of the particle whereas lysolecithin is transferred to plasma 
albumin. 'As the reaction proceeds, the cholesterol ester enters the 
non!X)lar rore pushing the bilayer apart until a spherical HDL is 
fonred. Cmlesterol esters fonn the rore while !X)lar lipids and 
apoproteins rover the surface. Cmlesterol as ester can rontinue to 
enter the particle until the source of HDL lecithin is exhausted 
(Tall & Small, 1978}. 'Ibis spherical HDL is not directly secreted 
b.lt probably derived fran HDL precusors by the action of I.CAT 
( Fbrte, 19 71 } • '!here appear to be four size ranges of spherical 
HDL; HDL-I; HDL-2a; HDL-2b, and HDL-3. The specific relationship 
between each is unknown • 
Plasma HDL may act as a source of Ap:> A-I to the bilayer folds 
and vessels as apo A-I is lcx,sely intergrated in the HDL particles 
(Tall, 1977}. In this manner the poospholipid derived fran 
chylanicron may be incor!X)rated in the HDL. '!he n<::M deficient A-I 
HDL becares thenrodynamically unstable and can fuse with another 
li!X)protein (Tall & Small, 1977} like chylanicrons thereby 
rontrib.lting their coolesterol ester rore to these particles. The 
fusion of unstable HDL with chylanicrons may provide a !X)Ssible 
route for the transfer of HDL cholesterol ester to the liver as 
chylanicrons rennants are avidly cleared by the liver (Anderson, 
1977} (see Figure 3}. 
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Figure 3. Possible nechanism for the transfer of surface rorrpcnents 
fran chylanicrans to HDI, fraction during lipolysis of chylomicron. 
Lipoprotein lipase hydrolyzes chylomicron triglyceride (lower Left). 
The surface of the chylomicron contains phospholipids, free cholesterol, 
A and C apoproteins (hatched bodies) and apo-B (labeled B). In 1, 
as triglyceride is removed, during lipolysis, the core shrinks, an 
the redundant surface constituents form lipid bilayer folds projecting 
from the chylomicron. In 2, a disklike particle could be formed 
directly from the apoprotein and phospho l ipids of the surface of the 
chylomicron. In 3, most of the excess material probably cones off 
as unstable bilayered sheets. In 4, these sheets seal to form 
vesicles. In 5,the circulating spherical HDL may interact with any 
of the redundant folds, sheets or vesicles donating A-I apoprotein. 
In 6, any of these structures are good substrates for the LCAT 
reaction if sorre apo A-I is present. The pool of HDL helps to 
convert the bilayer fragrrents to new spherical HDL. In 7, the 
apo A-I depleted spherical HDL has lost a large fraction of its 
surface and is thus unstable. It may fuse with other lipoproteins. 
In 8, if fusion occurs with the chylomicron, cholesterol esters could 
be transported back to the liver in the remnant (Tall & Small, 1978). 
Used by permission of the author. 
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'As HDL precusors are oonverted to spherical HDL, there may tea 
large influx of cholesterol in the HDL fraction. '!his may arise as 
a result of a chemical gradient for novement into the HDL precusors 
as there is a relative deficiency of cholesterol in the surface 
cx:mponents of chylanicrons and chylanicron derived HDL (Glicknan, 
1977; Redgrave,1978). 
The IC.AT reaction oould oonvert these cholesterol to 
cholesterol esters to form spherical HDL. 'llle rretal:x>lic fate of the 
HDL dlolesterol ester (HDL-<::E), at the rrarent, is unclear. 'As 
rrentioned atove, scree A-I deficent HDL may fuse with other 
lipoproteins and te cleared by the liver. A specific cholesterol 
ester-triglyceride exchange protein (ap:> D) may transfer HDL-a: to 
VIDL with a reciprocal back transfer of triglyceride (Chajek, 1978). 
In any case, HDL may protect against tissue cholesterol 
accumulation and atherosclerosis by providing a rrechanism for 
transfer of cholesterol fran the tissues to the liver as HDL may 
transport cholesterol form one tissue to another. Unfortunately, 
the exact relationship tetween HDL and atherosclerosis is not 
clearly understood. 
A~ently, toth IDL and HDL function together to maintain 
cellular balance of cholesterol; the IDL system brings cholesterol 
to the tissues (foward transport) while the HDL system renoves it 
(reverse transport). Based on epidirooligical evidence, it is 
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theorized tliat high levels of IDL with low levels of HDL are 
\ 
atherogenic while the reverse c:anbination oould decrease the risk of 
atherosclerosis. 'Ihis has lead sane to suggest that HDL may have a 
"protective effect" against atherosclerosis (Barr et al, 1951; 
Miller & Miller, 1975}. 
'lliE MEI'AEOLISM OF IN'ffiAVEN::>lE ~T EMUISIONS. Intravenous fat 
emulsions are similar to natural chylanicrons (100 to 800 nm in 
diarreter}. 'Ibey have a pale oore with an electron dense surface by 
electron microsoopy. danically, they oonsist of triglyceride 
emulsified with egg lecithin. 'Ihus, they can be thought of as 
synthetic chylanicrons. 'Ibey differ fran true chylanicrons in that 
they lack protein on the surface. lbwever, fat emulsions incubated 
in hurran plasma for a few minutes avidly acquire an ap:>protein (a[X> 
A,C,E} axnplerrent very similar to true chylanicrons (Hallberg, 1965; 
Ibberg & Hallberg, 1968; Havel, 1973; Robinson, 1979}. It appears 
that plasma HDL is the major a[X>protein d::>nor to the artifical 
chylanicron (Havel, 1973; Robinson, 1979}. The a[X>proteins becare 
ITOdulators of the rretalx>lism of the fat emulsion (Havel,1973}. 
Artifical chylanicrons are cleared in a manner similar to that 
seen for natural chylanicrons (Hallberg,1965}. '!he triglyceride 
oore of the artifical chylanicron is hydrolyzed to glycerol and free 
fatty acid by lip:>protein lipase prior to uptake by the tissues. 
The high ooncentration of lipid in the blood can stimulate in vivo 
-23-
release of r oothial lii;:oprotein lipase {Edgree et al, 1964; 
Fielding, 19 77) • 
Fbllowing an infusion of an intravenous fat emulsion, a 
i:errp:>rary hyperlipemia occurs. According to Hallrerg { 19 65) , the 
clearance of the fat particles {the triglyceride) in Intralipid fran 
the circulation in l::oth oogs and man is practically identical with 
the elimination rate of natural chylanicrons. Hallrerg sttrlied the 
elimination curve following an intravenous fat infusion in humans by 
separating the infused fat emulsion {exogenous triglyceride) from 
the endogenous plasma triglyceride. By establishing a density 
gradient, using i;:olyvinylpyrrolidone {PVP), the fat emulsion rose to 
the top of the tube with enoogenous triglyceride separating into two 
fractions in the lower i;:ortion of the tube. {Unfortunately with 
this rrethod it is difficult to identify the a:mposition of the 
enoogenous triglyceride in terns of whether it is a oomp:ment of 
VIDL, IDL, HDL, or if it is altered in all of them). At high 
roncentrations of infused lipids, maximal elimination of the 
triglyceride occurred, rreaning the enzyrre sites for the sul::strate 
are saturated and the reaction proceeds at a ronstant rate. 
Tre tenn "critical roncentration" {C nm:>le/ liter plasma) was 
roined to define when the optimal sul::strate concentration neccessary 
to reach maxium reaction capacity with the available enzyrre was 
reached. Al::ove this critical roncentration Hallrerg {1965) noted 
that there is a linear elimination rate {Kl nm:>le/ liter plasma/ 
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min) of th exogenous triglyceride; a zero order reaction. At 
levels below the critical roncentration, the rate of lipid clearance 
is dependent on the roncentration of triglyceride in the blood; a 
first order reaction. 
In sul::sequent sttrlies Hallberg (1965) noted that the clearance 
of an intravenous fat anulsion is influenced by the nutritional 
state of the subject. '!be maximal elimination in a :person who has 
fasted overnight ( 15 h::>urs) is approximately 3. 8 grarn.5 fat/kg/24 hr. 
After starving for 39 h::>urs, the elimination of the fat is 6 gm 
fat/kg/24 hrs. Wil.rrore (1973) noted an equivalent elimination 
capacity of 11.1 gm fat/kg/24 hr following a 48 h::>ur starvation 
:period in p:>st o:perative burn patients. 
SenDn triglyceride levels are at their highest level at the 
ronclusion of a fat infusion. Both Hallberg (1965) and MacFayden 
(1973) oooerved that the plasma triglyceride levels returned to 
preinfusion values within a matter of h::>urs following the ronclusion 
of the infusion. The rate of clearance of triglyceride fran plasma 
appears not to be dependent on the arrount of kcalories given in a 
simultanous TPN infusion (MacFayden, 1973). Kinney and associates 
(1980) in their work with nutritionally depleted patients and 
traurra victim5 suggest a preference in these patients to rretalx>lize 
fat (either en<i::>genous or exogenous) over glucose. 
Hallberg (1965) noted that in the fed state, when insulin 
levels are high, the synthesis of lip:>protein lipase is enhanced. 
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of insulin, lip:,protein lipase levels are low and 
e !XX)rly utilized resulting in hypertriglyceridemia. 
Heparin stimulates the release of lip:,protein lipase into the blood 
stream for rapid rercoval of the infused fat emulsion. Cbntinuous 
adminstration of heparin may deplete lip:>protein lipase and prolong 
clotting ti.Ire (~g, 1976). 
The exact fate of the triglyceride and phospholipid fraction of 
the intravenous fat emulsion is unknown. Freidrran and Byers ( 19 65) 
denonstrated that intravenous fat emulsion in rabbits causes a rapid 
rise in plasma cholesterol. '!'his resp:,nse was also seen when the 
liver was rercoved (Freidrran, 1957). Investigators a:mclt.rled that 
the extra phospholipid in circulation triggered cholesterol to be 
released into the plasma (Byers and Freidrran, 1958). 
Koga and associates (1974) intravenously fed three groui:s of 
puwies various c110unts of Intralipid (two, three, or four grams of 
fat per kilogram per day) in ronjunction with total parenteral 
nutrition for a period of eight to ten weeks. '!he total calories 
for each group was kept constant by increasing the carbohydrate 
(glurose) level as the fat a:xnposition decreased. A fourth group of 
puwies (control animals) was fed puwy chow. Within two weeks of 
infusing the fat emulsion, all group; recieving the fat denonstrated 
a marked increase in the plasma phospholipid, cholesterol and 
triglyceride levels. '!he above lipid levels returned to their 
inital levels five to ten days after cessation of the fat emulsion 
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infusion. The rcechanism involved could not be identified. The 
researchers stulated that there was an increase in the synthesis 
of alpha and beta lip:,proteins which lead to the enhancarent of 
lipid transp:,rt for uptake by utilizing tissues. 
The effect of fat emulsion on plasma lip:,proteins in healthy 
subjects was investigated by 'Ihlrpson and associates (1975). The 
subjects -were placed on an isocaloric, low fat diet to maintain 
constant -weight. In addition to the diet, they recieved 500 ml 
Intralipid intravenously over four oours for five consecutive days. 
Following the fat infusion, researchers noted a significant rise in 
the IDL coolesterol (P>.01} level. 'Ibis rould not be explained 
soley on the basis of coolesterol rontent of Intralipid which is 
less than 0 • 5 ~/ml. The rise in IDL cholesterol was accanpanied by 
a parallel increase in IDL protein. The researchers roncllrled that 
the increase in plasma IDL occurred as a result of the presence in 
the plasma of exogenous pix>spholipid fran the Intralipid. 
Using a similar research design, 'l'tanpson and rolleagues (1976} 
repeated their study to confirm the association bet-ween the rise in 
the IDL levels and the presence of exogenous pix>spholipid in the 
plasma. The investigators also stlrlied the rcechanism for the 
increase in IDL protein by rceasuring the turnover of I-122 and I-131 
labeled ap:>-IDL. There was no synthesis of ap:,p-IDL after 
intravenous Intralipid suggesting that the increase in IDL protein 
was ini tated by an influx into the plasma of pre-forrced IDL fran the 
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extravas lar a:xrparment triggered by the phospoolipid in Liposyn. 
Their res arch suggest that a possible relationship exists retween 
apo-LDL ca~lism and the fatty acid a:xnposition of LDL. 'Ibis has 
yet to re a:mfirmad. 
Researchers have noted a lipoprotein-X-like sul::stance 
appearing in the plasma following an Intralipid infusion in ooth 
rats and man. Lipoprotein-X (LP-X) is a unique low density 
lipoprotein with a characteristically high rontent of unesterified 
cholesterol and :p1ospholipid. It is found in the d 1.006-1.063 g/ml 
fraction of serum fran patients with bilary obstruction or familal 
lecithin: coolesterol acyltransferase (I.CAT) deficiency. In these 
patients, it is theorized that LP-X orginates in the intestional 
mucosa where it particpates in fat absorption. '!be cataoolism of 
lipoprotein-X is inhibited by the elevated bile acid levels present 
in bilary obstructive disease. LP-X accumulates. 
Breckenridge and asociates (1979) suggest that in the case of 
Intralipid infusion, LP-X is formad due to the accumulation of 
lecithin ( fran the fat anulsion) and cholesterol ester ( formad as a 
result of rrore sul::strates reing available for the I.CAT reaction). 
To determine whether this Intralipid induced lipoprotein-X was the 
sarre as authentic LP-X, Breckenridge et al (1979) infused fasted 
rabbits with 10% Intralipid for 24 hours and isolated the plasma 
lipoproteins. 'lbese were a:xrpared with animals with bile duct 
ligatures (to stimulate bilary obstruction) and fed animals 
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( rontro s) • Animals infused with Intralipid or with ligated bile 
ducts ha a 6 to 10 fold increase of free choleserol and 
phospholipi in the plasma. 'lbese changes were largely limited to 
the low density lip:>protein (IDL) which in toth group3 was 
indistinguishable fran each other. 'lbe IDL fran the Intalipid and 
the ligated bile duct animals appeared to b2 authentic lip:>protein-X 
in tems of their protein and lipid rontent and ca11EX)Sition as well 
as electrophoretic nobility. 'lbe authors ronclule that the 
lip:>protein-X acetnnulation in the plasma of the Intralipid infused 
animals was due to ina::mplete clearance of exogenous Fhospholipid 
which in turn nobilized tissue cholesterol and served as a lipid 
phase for ap:>protein peptides. 
Miyahara and associates (1979) identified a lip:>protein-X-like 
sul:stance in 42 out of 43 surgical patients recieving Intralipid. 
Tre reseachers limited their investigation to electrophoresis and 
electron microscope stulies of whole plasma and lip:>proteins. 'Ibey 
did not determine the chemical exxtq?Osition of the IDL fraction to 
determine its similarity to authentic lip:>protein-X. 'lbese results 
have yet to b2 ronfinred in a similar p:>pulation group. 
'll1e question of the exact response ·of the b:>dy' s l.ip::,protelns 
to an intra-venous fat ernulsim .has not been systematically examined. 
Research suggests than an infusim of phospholipid will liberate 
dlolesterol fran the body tissues. 'lbgether the ph:>spholipid and 
mesterified dlolesterol can beoate substrates for the LC.AT reactim 
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whidl in tum can increase the levels of circulating spherical IIDL. 
The literature further inplies that the I:IDL dlolesterol ester nay be 
nonenzyrnatically transferred to chylomi.crcns and VLDL whose rennants 
are cleared by the liver. '!his may provide the nedlanism for the 
rerroval of cholesterol ester. If such a nedlanism does occur with 
the use of intravenous fat emulsions, it may have far readling 
inplications in the treabtent of diseases su:h as atherosclerosis. 
EXPERIMENTAL DESI~ 
SUBJECI'S. Subjects were selected fran patients referred fran 
the nedical and surgical services at University Hcspital to the 
Clinical Nutrition Unit (CNU) for nutritional supp::,rt. 
These adults, three females and one male, were unable to eat 
nonnally and required parenteral nutrition (TPN) as their sole 
source of nutrients (Table 1 & 2) • None of the patients had been 
recieving rredication kna.vn to affect lipid netatolisrn. Also, the 
subjects had no kna.vn disturbances of fat netatolisrn nor liver or 
pulmonary involvarent as the use of intravenous fat anulsion is 
oontra-indicated in such rredical conditions (Jeejeebooy et al, 1976; 
Hidalgo, 1976; Freund et al, 1975). 
Proper infonred consent was obtained using forns and procedures 
approved by the lbston University M:rlical Center's "O:mnittee to 
Review AJ;:plications for EKperiental Reseach Involving Hman 
Subjects" before any blood samples were drawn. (See AWendix.) 
Primary I_)atient care remained the resp:,nsibility of the 
subjects' attending i;::hysician. All st\.rlies were integrated directly 
into usual patient care and net with the approval of the attending 
physicians. 
Each patient served as his/her own oontrol. 
The nutrient needs of each subject were detennined based on 
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their ight, weight, degree of weight loss, rredical condition and 
the stre \ that each of these ronditions imp:,sed on their nutrient 
needs. (Stress code is a rreans of estimating the degree of stress 
that a patients' rredical condition and treabrent is imp:,sing on his 
nutritional status (Geller et al, 1979)). The goal is to adequately 
supp:>rt the subjects' nutritional needs in order that the bi--v.eekly 
fat infusion not be used as a primary energy source. 
SUBJECI' FF. A sixty year old female with a thirty year history 
of multiple sclerosis was admitted for treabrent of an acute urinary 
tract infection and surgical repair of a vesecoenteric fistula. At 
the tine of admission, she was experiencing dehydration and 
rretal:x>lic acidosis. With the rorrection of the fluid and 
electrolyte imbalances, her total protein (5.5 mg/dl) and albumin 
(2.2 mg/dl) levels remained depressed. The low protein values and a 
recent weight loss of twenty three pounds classified her as 
rroderately malnourished. It was decided to support her 
nutritionally via total parenteral nutrition tmtil her urinary tract 
infection resolved. At that tine, a descision "'10uld be made 
roncerning surgery for repair of the fistula. 
Based on current weight of 122 p:>unds for a height of 5 feet 6 
inches and a stress code of one, 2,230 kcalories with 60 grams of 
protein was given. Once total parenteral nutrition was infusing at 
the optimal rate and electrolyte values were within nonnal limits, 
the fat stooy was inititated. 
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FS. A seventy year old wanan was admitted for a 
gastroeso~gostany as treatnent for gastric carcincma with 
esophageal ol::struction. She was cachetic and anorectic and had lost 
thirty five p:>\mds over the eight week period prior to admission. 
Laooratory studies showed a rroderate anemia with low total protein 
(5 gm/dl) and alb..nnin (2.5 grvdl). 'lbtal parenteral nutrition was 
instituted to restore the protein values to within normal limits 
before surgery. Based on a height of 5 feet one inch, a current 
weight of 99 p:>unds and a stress a::xie of three, she was given 2,085 
kcalories with 75 grams of protein. Within one week, the TPN 
infusion rate was at llB.Ximum and infusing witlx:>ut difficulty. On 
day ten, the fat stlrly was begun. 
SUBJECT AD. A thirty eight year old male was admitted for 
treatnent of a pancreatic p:;eudocyst secondary to alcohol arose. 
Due to severe al:rlaninal pain, he was placed on total parenteral 
nutrition to avoid stimulation of the pancreas. Physical 
examination revealed fullness in the left l.lfP=r al:rl:men. Vital 
signs were within normal limits. Iaooratory studies showed 
chronically elevated LOH and SOOI' with a rroderately depressed total 
protein ( 5 • 7 gm/ dl ) and alb..nnin ( 3 • 0 gm/ dl ) • Based on a height of 
5'6", a current weight of 123 p:>unds with a weight loss of seventeen 
p:>unds, and a stress a::xie of one, 2,700 kcalories with 77 grarrs of 
protein was given. 'I'he fat stlrly was initated once the TPN solution 
was stabilized at optimnal rate witlx:>ut difficulties. 
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BA.SELINE DAYS. Each patient had been referred to the Clinical 
Nutrition Unit (CNU) and a routine determination of nutritional 
status was ma.de according to the Nutriticn Assessrrent Profile 
(Geller ,1979). Based on this assessrrent, a nutritional care plan 
was established defining the patient's daily caloric and protein 
neErls. If indicated, a central surclavian catheter was inserted and 
its plaCE!fCErlt in the surclavin vein d:>currented by radiography. '!he 
patient was closely rronitored by the ~ical staff lIDtil the 
infusion of the total parenteral nutrient solution stabilized as 
indicated by blood electrolytes and glucose levels. In this study, a 
TPN solution a:mtaining 25% dextrose and 4.2% amino acids with 
standard electrolytes, vitamins, and minerals was given. '!he 
standard infusion rate was 50cc per h::>ur on the first day with an 
increase of 25cc per oour per day lIDtil optimum infusion for the 
particular patient was reached. 
Once stabilized the patient was asked to participate in this 
project and a signed consent was obtained. 
EXPERIMENTAL DAYS. '!he TPN solution was infused at its 
preestablished optimum rate; infusion punps were used to guarantee a 
ronstant infusion rate. 
An indwelling intravenous needle with heparin lock was inserted 
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to allow fo \ t ultiple blood samples. In the opposite ann, the 
intravenous fa t,____emulsion was infused at the intial rate of one 
milliliter per minute (1 ml/min) for the first 15 minutes of 
infusion. If the subject exhibited no untoward reaction to the fat 
emulsion, the infusion rate was increased to 125cc per oour so that 
500 ml of Liposyn (Al:xx>t Lab:>ratories, Chicago, Illinois) was 
infused over a period of four oours. In this group of patients 
whose average weight was 48.9 kilograms, 0.256 grams triglyceride 
per kilogram per oour was given. Each 100 ml Liposyn rontained 10 
grams triglyceride as safflower oil, 1.74 grams lecithin, 0.08 grams 
free cholesterol and 3 .13 grams glycerine (Tables 3 and 4) • 
Through the indwelling peripheral catheter, one blood sample 
was drawn .i.rmediately pre-fat infusion into chilled tubes 
rontaining 15 milligrams disodium ethylenediaminetetraacetic 
acid (EDTA). (EDTA sequesters the divalent rretallic ions that 
prarote autoxidation of unsaturated fatty acids in blood lipids 
(Nelson,1972)). One milliliter of ten percent heparin solution was 
withdrawn before the blood samples were taken as heparin may 
stimulate activity of lipoprotein lipases that may be in the plasma. 
(Plasma samples are preferred over serum, as allowing the blood to 
clot before cells are separated frcm serum may p:rarote the activity 
of plasma lecithin: cholesterol acyl transferase ( ICAT) • This enzyrre 
alters the serum lipid patterns of cholesterol, cholesterol ester, 
lecithin and lysolecithin (Nelson,1972). Blood samples were drawn at 
pre-fat infusion (tine 0), and 1/2, 1, 2, 4, 6, and 18 hours 
-35-
following the inital infusion of the fat emulsion to oocurrent the 
clearance of the fat emulsion. Blood sarrples drawn at time 0, 1, 4, 
and 18 allOYS:1 further studies for total plasma. lipids and 
lip:::>protein chemical composition (Figure 4). 
SUBJECl'S 
FF 
FS 
AD 
'IS 
TABLE 1 
OIARACTERISTICS OF SUBJECI'S 
lbs PREM>RID STRE'SS 
SEX Arn HEIGIT WEIGil' WEIGIT' CODE 
F 62 5'6" 122 145 1 
F 70 5'1" 99 135 3 
M 38 5'6" 123 140 1 
F 65 5'0" 86 163 3 
BEE: Basal Energy Expenditure (kcalories) 
IEI : Ideal Energy Intake (kcalories) 
IPI: Ideal Protein Intake (grams) 
BEE IEI 
1,201 2,005 
1,069 2,085 
1,404 2,247 
1,063 2,072 
-
IPI DIACN)SIS 
60 Vesecoenteric 
fistual to the 
lower ileun 
75 Gastric cancer with 
escphagal oostructicn 
77 Pancreatic 
pselrlocyst 
56 Eso:(il.ageal canrer 
with ccrcplete 
obs~ticn 
Stress Cbde: a ~ans of estimating the degree of stress that a patient's ~cal 
cx:nditicn and treabrent is inposing en his nutriticnal status (Geller et al, 1979) 
I 
w 
°' I 
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TABLE 2 
CLINICAL LABORA'.IDRY VALUES 
SUBJECI'S 
BIOOD VAll1ES FF FS AD 
HCT 35.0 31.0 32.6 
(37-47 ml/dl) 
Hb 11.4 10.0 11.0 
(12-16 gm/dl) 
me 3.64 3.6 3.73 
(mill/cu rnn 
WBC 15.2 5.2 10.4 
Platelets 407,000 354,000 281,000 
(140-430/cc rnn 
Sodium 136.0 137.0 134.0 
(131-148 rrEq/1 
Fbtassiun 4.7 4.3 4.1 
(3.6-5.6 nEq/1) 
Chl.oride 112.0 105.0 96.0 
(95-105 nE/1 
Rancbn Gl"t£ose * 74.0 112.0 155.0 
Calcium 8.2 8.9 8.4 
(9-11 rrg/dl 
Total Protein 6.1 5.0 5.7 
(6-8 gm/dl) 
Albumin 2.2 2.5 3.0 
(3. 5-5 gm/dl) 
'lbtal bilir'li>in ND 0.9 4.1 
(0-1. 0 nq/dl) 
*Rancbm gl'l£ose drawn while patient is recieving TPN 
**lbt oone 
TS 
29.7 
9.7 
3.l 
4.4 
225,000 
140.0 
4.8 
106.0 
147.0 
8.8 
5.7 
3.0 
0.9 
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TABIE 2 
CLINICAL IAOORA'IDRY' VAllJF.S 
-ccntinued-
SUBJECT'S 
BI.O)D VALUE.5 FF FS 
BUN 20.0 19.0 
(5-20 ng/dl) 
Creatinine 1.2 0.7 
(0. 5-1.1 ng/dl) 
I.DH ND 125.0 
(30-125 u) 
S001' ND 52.0 
(1-40 u) 
Plasll\3. Volute (ml) 2,385 1,935 
assure 43 ml/kg 
AD TS 
13.0 17.0 
0.7 0.8 
97.0 104.0 
68.0 27.0 
2,404 1,681 
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TABIB 3 
1 
(XM)()SITICN OF LIPOSYNR 
10% Saffla-ler Oil 
77 % lirnleic 
13 % oleic 
7 % palmi.tic 
2.5 % stea.ric 
1. 2% egg phosphatides 
2.5% glycerin 
Sodium hydroxide 
1From infonnation supplied by 
Aboott Laboratories, Oiicacp, Illinois 
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TABLE 4 
LIPID CXMPCSITION OF ~ 
DERIVED FROM 
THIN LAYER CHROMATOGRAPHY 
Amollllt in one bottle (500 ~l) LIPOSYNR 
* 
** 
*** 
9.0% 
1.0% 
0.64% 
Weight%* 
Triglyceride** 
Lecithin*** 
Free cholesterol 
Weight%; gm/100 gm LiposynR 
Triglyceride is safflower oil which is 
77% linoleic acid as determined by 
Abbott Laboratories 
Lecithin by TLC (Downing,1968). A 50 ugm 
spot showed only phosphatidyl choline 
Day 
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FIGURE 4 
EXPERIMENTAL DESIGN FLOW SHEET 
_______ T_P_N SOLlJfION INFUSION 
1 2 3 4 5 6 7 8 9 10 11 
Baseline Days: 
■Fat emulsion 
Patient referred to Clinical Nutrition Unit for 
nutrition assessment 
If indicated, TPN 1~ 
inserted, solution infusion 
rate stabilized 
l 
Tube Feeding if indicated 
Patient asked to oarticipate----~) If no, patient continues in research proJett I with nutritional support 
--..J....- as outlined for them . 
If agrees, patient signs 
consent form 
j_ 
Experimental Days: Collection period #1 
IndwelJng catether inserted in arm opposite from 
intravenous 10% fat emulsion infusion for timed 
blood drawing at pre-fat infusion (time 0), 
1/2. 1, 2, 4, (end of fat infusion), and hour 
18 (post fat infusion) 
J; 
Intravenous fat enulsion begun. Patient 
observed for adverse.reactions, if none 
~ 
Fat infusion rate increased to 125 cc/ hour to allow 
for 4 hour infusion. Blood drawn at pre-established 
times (pre ,during, and post fat infusion) 
J 
Collection period# 2 
Procedure repeated 2 days later on each subject 
LIEOPROTEIN ANALYSIS. Collected blcx:x:1 samples were cnoled on 
ice .i.ntrediately after collection and centrifuged (M:xiel PR-2, 
International E:;Juiprent, Needham Heights, Massachusetts, 02194) at 
1200 rpn for minutes at 4 • C. Centrifuged plasma was separated fran 
red blcx:x:1 cells with a Pasteur pipette, transferred to a fifteen 
milliliter (15 ml) screw top scintilation vial with a teflon liner 
in the cap. All samples were stored tmder a layer of nitrogen (to 
excl ,uie oxygen to prevent autoxidation) in the dark at 4•c within 
one hour of collection. All plasma samples were assayed within 
twenty four hours of collection (Figure 5). 
Plasma li!X)proteins were separated according to the method 
established by Bronzert and Brewer (1977). A 180 ul aliqoot of 
plasma was added to six micro-rellulose tubes (Beckman Instrurrents 
Inc., Palo Alto, California,93494). Fbur clear tubes were at plasma 
density (1.006 ng,/2nl) to allow the VIDL-lipid ramant fraction to 
float to the top of the tube with the IDL and IIDL in the oottan 
fraction. Two green tubes were coated with 13.8 milligrams of 
!X)tassium branide (KBr) to adjust 180 ul of plasma to density of 
1.063 ng/dl. Plasma centrifuged at this density contains the 
VIDL-lipid ramant and IDL in the top fraction with the HDL in the 
infranate. 
All plasma samples were pre-stained by the addition of one 
micro-liter (1 ul) of activated Red Fat 7B (Sigma Chemical Canpany, 
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St. IDuis , M:>. , 63178) to the 180 ul of plasma. Sarrples -were mixed 
on the Beckman Airfuge Tube Fractionator ( Beckman Instnnrents Inc. , 
Palo Alto, California). '!he plasma was centrifuged in an air driven 
centrifuge (Airfuge; Beckman Instnnrents Inc., Palo Alto, 
California) at 28 psi (100,00 rpn) for 2 1/2 hours at 25•c. 
After centrifugation, the VIDL-lipid rennant was rem:>ved fran 
two clear tubes and the I<Br tubes by aspiration on the Beckman 
Airfuge Tube Sipper. 'Ibis left the IDL-HDL fraction in the clear 
tubes and only HDL in the I<Br tubes. '!he VIDL fraction was rem:>ved 
by laml:rla pipette fran the remaining two clear tubes and reserved 
for chanical analysis. 
'lb the two clear tubes containing the IDL-HDL fraction, 50 ul 
of 1.214 gnv'ml KBr was added to adjust the density to 1.063 ng/ml 
and re-centrifuged at 28 psi for 2 1/2 hours at 25° C allowed for 
separation of IDL fran HDL. '!he IDL fraction was rem:>ved by 1arnl::rla 
pipette and reserved for chemical analysis. 
Fifty microli ters ( 50 ul) aliqoot of whole plasma, VIDL-lipid 
rermant, IDL and HDL fractions was placed in a glass stopper 
thirteen milliliter ( 13 ml) conical tube in preparation for chemical 
analysis. 
Cll)LESTER)L DEI'mMINATIONS. Coolesterol was determined on 
wtx>le plasma, IDL-HDL, and HDL fractions with a Beckrran Coolesterol 
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Analyzer (Beckrran Inst.n.ments Inc., Fullerton, California, 
92634) (Bronzert and Brewer, 1977). A mixed enzyrre reagant of 
cholesterol oxidase and esterase and plasma. lipoprotein samples were 
directly added to the reaction chamber oontaining sodium phosphate 
ruffer. 
The Beckrran Analyzer is an enzymic oxygen electrode coolesterol 
analyzer. In this system, coolesterol esterase (Becknan Inst.n.ments 
Inc.) is used to hydrolyze coolesterol esters to free cholesterol. 
Coolesterol is oxidized with coolesterol oxidase (Beckrran 
Inst:rurrents Inc.) to coolest-4-en-3-one and hydrogen peroxide. '!he 
analyzer measures the rate of oxygen CXXIEurcption with an oxygen 
electrode. '!he oxygen oonsurred is directly proportional to the 
total ooncentration of coolesterol present in the sample. 
The cholesterol oxidase and cholesterol esterase as the mixed 
enzyrre solution is stable for ooe week at 4° C. 'lhe Beckrran 
Coolesterol Analyzer is calibrated with an aqueous coolesterol 
standard (220 mg/dl; Becknan Inst.n.ments Inc.) before sample 
detenninations are ma.de. 
After centrifugation in the Airfuge, the cholesterol in the 
lipoprotein fraction (IDL-HDL and HDL) as well as whole plasma. is 
detennined by adding 5 ul of sample and 10 ul of enzyrre mixtrure to 
1 ml phosphate ruffer in a reaction cell at 37°C. 'lhe rate of 
change in oxygen oonsurcption is rreasured and a digital readout in 
-45-
mg/ell is displayed. 
The cholesterol rontent in each of the lip::>protein fractions is 
calculated directly or by subtraction as in the case of VIDL and 
LDL. IIDL cholesterol is rreasured directly in the infranate of 
plasma centrifuged at density of 1.063 mg/ell: IDL cholesterol equals 
the value obtained from the infrante of plasma centrifuged at 
density of 1.006 (IDL plus IIDL) minus the IIDL cholesterol values. 
The VIDL cholesterol equals the total plasma cholesterol values 
minus the values for LDL plus HDL cholesterol. 
Sc1I1ple Calculations 
Direct results frorn Beckrran cholesterol analyzer 
Data: wtnle plasma =200 ng/ell 
Bottan Fraction of 1.006 grrv'ell =260 ng/ell 
( clear tube) LDL + HDL 
Bottan Fraction of 1.063 grrv'dl = 70 ng/dl 
( green tube) HDL 
The values for LDL and IIDL represent a roncentrated sample as a 
result of the centrifugation procedure. Both values must be 
returned to the original plasma volurre. 'Ibis is ·cbne by multiplying 
these values by a rorrection factor. 
The rorrection factors are detennined by gravirretric analysis 
of the percentage of the sample left after sipping off the top layer 
on the Beckrran Airfuge Fractionater. Fbr the roncentrated 
lip::>protein sarrq;>les, the factors are 0.7174 for the clear tube (d 
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1.006 ng/ml) and 0.6211 for the green tubes (d 1.063 ng/dl). 
CDRRECT'ED VALUES 
Plasma = 200 ng/dl 
LDL + HDL 260 x 0. 7174 = 187 ng/dl 
HDL 70 x 0.6211 = 43 ng/dl 
By subtraction the final values are: 
Plasma.= 200 ng/dl 
VIDL = 13 ng/dl 
LDL = 144 ng/dl 
HDL = 43 ng/dl 
PREPARATION OF LIPID SAMPLES • Lipids f ran the plasma and 
lipoprotein samples extracted in ten milliliter (10 ml) of 
re-distilled chlorofonn--nethanol (2:1 vol/vol) after which a Fblch 
procedure was carried out to rercove any protein in the samples 
( Fblch et al, 19 5 7) • '!be samples were dried d:>wn under a stream of 
nitrogen to a:rnplete dryness and brought back to volurre by adding 
500 ul 2:1 re-distilled chlorofonn--nethanol. 'Ibese prepared lipid 
samples were used for thin-layer chranatography and i;nosphate 
assays. 
LIPID ANALYSIS. Quantative thin-layer chranatography was used 
to neasure the free coolesterol, triglyceride, coolesterol ester, 
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lysolecithin, sphingcmyelin, and px>spootidyl cooline (Dc:Mning, 
1968). Pyrex plates, 20 x20 an, with 0.25 rnn silica gel G was 
divided into thirty lanes, 6 rnn wide. After washing in diethyl 
ether, the plates were activated for thirty minutes at 120°C and 
sarrples applied in triplicate on two separate plates. A standard 
solution of coolesterol, triglyceride, cholesterol ester (Nu--ch:ck 
Prep, Elysian, Minnesota), sphingcmyelin (Lipid Products, South 
Nufield, England), lysolecithin and phosphotidyl cooline (J'\Wlied 
Science, State College, Pennsylvania) was applied to three lanes on 
each plate, interspersed at regular intervals with the samples. The 
concentration of each lipid was approximately one microgram per 
microli ter ( 1 ug/ul) • Dry weights of samples and standards were 
used to ensure that not rrore than ten micrograms (10 ug) of a given 
lipid class was applied to each lane. One of the two plates was 
developed in a solvent system of hexane, diethyl ether and acetic 
acid (70:30:1, vol/vol/vol), to separate the coolesterol, 
triglyceride, and cholesterol ester. '!he second plate was developed 
in a solvent system of chloroform, nethanol, water and acetic acid 
(65:25:4:1, vol/vol/vol/vol) to separate the lysolecithin, 
sphinanyelin, and {ilosiix>tidyl choline. After developrent, the 
plates were allowed to dry; then sprayed with 50% sulfuric acid and 
heated to 220° C for forty five ( 45 } minutes. '!he charred Lipid 
spots were scanned with a photodensitareter (Pootovolt Corp., New 
York) and the area under the peaks was neasured and canpared to the 
standard's value to determine total percentages of lipid classes 
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present. 
IKSPHATE ASSAY. A 50 ul of the folched lipid was analyzed 
according to a rrodif ied Bartlett rrethod ( 19 59 ) • '!he lipid sample as 
placed in a test tube and dried d:Jwn in a 165 °C oven. 'lb the dried 
samples, 0.5 ml of 8N H2S04 was added to the digest samples and 
heated for four h::>urs in a 165° C oven. 'llle color was developed by 
adding O .22% armnnium nnlybate and Fiske-Subbarow Reagant to the 
samples and heated in a toiling water bath for twelve minutes. TD: 
samples were allowed to cx:x:>l for twenty minutes and then read on 
Beckman Spectroli1areter at 800 mu. 
STATISTICAL ANALYSIS OF DATA. Inherant within clinical stlrlies 
are three main sources of data variation of the data. 'lllese are 
true biological variation, tenporal variation, and rreasurenent 
error. 
True biological variation represents individual differences of 
each subject such as their age, sex, genetics, and past rredical 
history. Factors such as €!l0tional state, activity state or 
circadian rhythrrs that cause variation in observations within an 
individual are known as tenporal variation. Measurenent error 
concerns all factors that may produce differences in rreasurenent of 
the sane phenarenon such a rreasuring tools, technican error or 
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laooratory ronditions (Colton, 1974). 
One way to reduce these variation is to make duplicate 
determinations on all of the experirrental procedures. Fbr this 
reason, two rollections with multiple sampling i;:oints were made on 
each of the four subjects (n=8). 
Analysis of variance (.ANOVA) is another way to isolate and 
assess the rontribution of different factors to variation of data. 
~ F value for 'NlOVA is derived frc:xn the variance betwen group; 
divided by the variance within group;. 
F = Variance between grou:p;/Variance within groups 
The variances between group; represents differences due to the 
experirrental variances, while variance within the group; considers 
the measurement error variation, biological variation and temperal 
variation. 
Fbr this sttrly, repeated rreasures of analysis of variance 
(l!NOVA) with a trend analysis was used. 'Ibis type of analysis will 
yield several areas of significance. First, it answers the 
question; Are there differences between the group; at each of the 
four tine periods? Secood, the rreans for all subjects at each tine 
is plotted and a line drawn ronnecting those i;:oints: Is the shape 
of the line (either linear or quadratic) a real phenaren, and 
therefore significant? '1hese two area of significance are 
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ronsidered in the results and discussion sections. 
The Student's t test was used in a few situations to detennine 
the degree of significance between group3 at~ different time 
periods. 
FIGURE 5 
Blood sanples are drawn at timed intervals through an indwelling intravenous needle into chilled 
blood tubes containing EDTA. 
Blood sanples spun at 1200 rpm for 20 minutes at 4°C to separate red blood cells from the plasma. 
Renove the plasma via a pastuer pipette. Place in a 15 ml scintilation vial. (For samples not 
analyzed immediately, top with nitrogen gas and store in the dark at 6°C.) 
TURBIDITY ASSAY 
Whole plasma Jiluted (1/10) 
with normal saline for times 
0,~,1,2,4,6, & 18 hours. 
Read at 536 mu. 
-¥ 
WHOLE PLASMA ANALYSIS 
Whole plasma from timed 
sanples for hl urs 0,1,4, & 18. 
Lowry Prote fn Cl1olesterol 1. Assay 
Folch Procedure / 
Phosphate ~ ~ TLC' 
Assay j 
LIPOPROTEIN ANALYSIS 
Place 180 ul of whole plasma for sanples 0,1,4, & 18 hours into 
6 micro-air fuge tubes (4 clear; d. 1.006; 2 green; d.1.063). Add 
1 ul red fat stain 7B. Mix. Spin in Beckman Airfuge at 28 psi 
100,000 rpm) for i "' 1!._ou ~ 25 ° C. 
From 2 clear tubes ( .l.006) . ~ From 2 clear tubes (d.l.006) 
hand renove VLDL layer & pool renove VLDL layer via Beckman 
sarcples from both tubes.* Airfuge Tube Fractionator. 
"---..1 ,,I/ 
Lowry Protein ~olch Cholesterol Assay 
Assay --Procedure '1-· 
~..........----i Adjust density to 1.063. Respin 
.Phosphate TLC at 28 psi for 2~ hours at 25 ° c. 
bsey ~ 
*(Absolute cholesterol values to 
be derived from plasma, LDL-HDL, 
& HDL values.) 
By hand, renove LDL layer from 
both tubes and pool samples 
Lowry Protei ~ Folch 
Assay Procedure 
~ 
From 2 green tubes (d.l.063)sip off 
top layer of VLDL & LDL via Beckman 
Airfuge Tube Fractionator to leave 
HDL f~action ~-~ ----- -
,i-
Phosphate TLC 
Assay 
~Folch Procedure 
- , /' ' _J 
Phosphate TLC 
Cholesterol Assay Assay 
SUMMARY OF ANALYTICAL PROCEDURES 
I 
V1 
I-' 
I 
RESUL'.I'S 
CLEARANCE OF 10% FT\T .EMUI.SION FR0-1 'IHE PLASMA. During the 
infusion of the 10% fat anulsion, the turbidity of the woole plasma 
(as rreasured by spectroinotaretry) was significantly increased 
(P<.001). At the end of the infusion (oour 4), the turbidity 
reading was the highest. 'lw:> oours after cessation of the fat 
anulsion (oour 6), the plasma values had dropped to 0.65 mu; al.roost 
the sarre values as the first oour of the infusion. By oour 18 (14 
oours after cessation of the fat anulsion infusion), the turbidity 
of the plasma had returned to the pre-infusion baseline values 
( Figure 6) • 'Ille shape of the graph line and variances between and 
within the group:; are significant at P<.001 (Figure 6). 
Plasma triglyceride values for each subject were detennined 
indirectly. By adding various am:>unts of Liposyn to vitro samples 
of hUITBn plasma and reading the turbidity on the spectroinotareter, 
it was possible to develop a standard curve for the ooncentration of 
triglyceride in plasma (ng/dl; Figure 7). By a:xrparing the optical 
density fran the subjects to the standard curve, the subjects' 
triglyceride (ng/dl) was calculated (Figure 8). 'Ibis derived value 
was cxxnpared to a theoretical event ( Figure 8) • Assuming the 
triglyceride anulsion was not rem:>ved fran the system during the 
infusion b..It rather dispersed itself evenly throughout the plasma, a 
linear increase in plasma triglyceride is suggested. 'Ibis 
projection is cxxrpared to the actual event. 'Ille difference bet\\1een 
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these events is used to approximate the clearance of the fat 
emulsion (triglyceride) fran the system. 'lllese subjects appeared to 
clear, roughly, 0.2435 <Jll tg/kg/hr. 
EFFECT OF 10% ThT EMUISION 00 PI.ASMA AND LiroPOOTEINS. 
PI.ASMA. During the infusion of the fat emulsion, a drop in 
total coolesterol values, as neasured by the oxidase ~thod (Tables 
5 & 6, Figure 9) , was seen fran oour 0 to oour 1 with a gradual 
rise to baseline values by oour 18 (P<.01). 'Ibis decrease was 
reflected in the cxxrposition (percentage and rrg/dl) of l::oth free and 
esterified coolesterol (P<.001) in plasma (Tables 5,6, & 7; Figures 
11 & 12) • W1en collections 1 and 2 are axnpared ( Figure 13) , this 
~ decrease is observed in free and esterified coolesterol with a 
gradual rise to baseline values by oour 18. '!be fat emulsion 
infusion caused a decrease in the total (rrg/dl; Figure ll; P<.05) 
and relative(%; Figure 12; N.5) canposition of i;nospoolipid with a 
return to baseline values by oour 18. 
p 1.006. This fraction floats at plasma density. At this 
density, using the Beckman Airfuge system, it is not p=>ssible to 
separate the fat emulsion particles fran the very low density 
lip=>proteins. It is assurred that few if any chylanicrons are 
present in plasma samples as the subjects received nothing by nouth. 
In this fraction, the coolesterol values during the fat 
infusion as detennined by enzymatic assays~ a non significant 
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decrease (Table 5; Figure 9). The relative a:xcp:>sition derived by 
thin layer chranatography showed a significant increase in the 
triglyceride level within the first oour of the infusion (Table 7; 
Figure 14). 'As the proJX)rtion of triglyceride increased, the 
percentage of free coolesterol, esterified cholesterol and 
phospholipid gradually decreased and returned to pre-infusion levels 
by oour 18. 'Ibis trend was reflected in oollections 1 and 2 ( Figure 
15). 
p 1.006 < d < 1.063. This fraction represents the IDL 
fraction. Visually this fraction was still quite cloudy, indicating 
that sate of the fat emulsion was in this area. 
'As detennined by the oxidase coolesterol assay, the total 
coolesterol (ng/dl) rose slighlty and oontinued to increase 
gradually to oour 18 (Table 5; Figure 10) • 'Ibis resJX)nse was not 
significant. '!be slight increase in total coolesterol values was 
not reflected in the relative <Xf1l)OSition (%) of l:x>th free and 
esterified cholesterol (Table 7; Figure 16). Here the cholesterol 
percentage for l:x>th free and esterified, was decreased during the 
infusion and gradually climbed to baseline values by oour 18. 'Ihe 
phospholipid values did not change significantly during or after the 
fat infusion (Table 7; Figure 10) • 
p 1.063 < d < 1.21. The infusion of the fat emulsion caused 
a slight but non significant decrease in the HDL coolesterol values 
(ng/dl) with a gradual rise to baseline values (Table 5; Figure 10). 
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This trend was reflected in the relative cnrpostion ( % ) of free and 
esterified cholesterol levels (Table 7; Figure 18). The percentage 
of HDL triglyceride was significantly increased (Table 7; Figure 18; 
P<.005) during the fat infusion and gradually dropped to baseline 
values by hour 18 (Table 7; Figure 18; P<.005). The phospholipid 
percentage decreased and returned to baseline values by hour 18 
(P<.025). These trends -were not clearly reflected in oollections 1 & 
2 (Figure 19). 
By the end of the fourth oour of the fat infusion, the results 
in this study show a large increase in triglyceride (290%) and a 
slight rise in free cholesterol ( 8.5%) and phospholipid ( 3.4%) in 
the plasma fraction. In the I.DL fraction the cholesterol (5%) and 
phospholipid (6%) levels decreased. 
The subjects in this sttrly are malnourished as oocurrented by 
the low total protein, albumin, and low -weight for height (Table 1 & 
2). Since fluid volurre is directly related to -weight (43 ml/kg oody 
-weight), it was believed that the addition of 500 ml of fluid \11,1()Uld 
affect fluid status, thereby diluting plasma values. The average 
-weight of the group is 48.86 kg; therefore the average inital fluid 
volurre is 2101 ml. By hour 1, the fluid volurre increased by 125 ml 
to 2226 ml and by hour 4 to a final average volurre of 2601 ml. 
Based on these values, a dilution oorrection factor for hour 1 of 
1.06 and hour 4 of 1.20 was derived. '!his was applied to the group 
neans for hours 1 and 4 rep:>rted for total lip:>protein cholesterol 
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values (Table 5) , total plasma values (Table 6) and lipid 
CXfIPOSi tion of serum lip:>proteins (Table 7) • As a result of these 
manipulations, the data takes on the characteristics rep:>rted in the 
literature. 
In the plasma by oour 4 of the infusion, triglyceride levels 
increased 3 .5 tines while unesterified coolesterol increased by 69% 
and phospholipid by 67%. 
This strong resp:,nse applies to all the lip:>protein fractions 
(Table 5; Figure 20). In VIDL, free coolesterol increased by . 63% 
'· , 
triglyceride by 64% and phospholipid by 59% (Table 8; Figure 
22) . '1he biggest change appeared in the IDL fraction. ' '1he raw data 
showed a decreased in phospholipid and cholesterol (free and 
ester if ied) • After correcting for dilution, the free cholesterol 
~ / ;.,~1-::. \ 1 --;._.r • 
increased 46%, triglyceride 65%, esterified cholesterol 74%, and 
:,; ~ I 
phospoolipid 53% (Table 8; Figure 23). The values for IIDL 
oontinued to oold true after correction. '1he triglyceride values 
increased while ptx:>spholipid and coolesterol (free and esterified) 
decreased (Table 8; Figure 24) . 
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TABLES 
TCYI'AL IPOPROTEIN CHOLESTEROL VALUES* 
Time Cholesterol Time Conputed 1 
Hours mg/dl Hours Cholesterol 
Plasma 0 132.94 ± 12 . 07 0 132 . 9 
1 125. 06 ± 13.12 1 132 . 5 
4 130.75 ± 12.03 4 161. 87 
18 146.13 ± 18.09 18 146.1 
2 P< .01 :3 
P <. 025 
VLDL 0 67 . 11 ± 20. 85 0 67 .11 
1 51.98 ± 14 .2 7 1 55.07 
4 67 .68 ± 9.51 4 82.94 
18 64.43 ± 15 .15 18 64.43 
N.S . 
LDL 0 45 . 19 ± 23.50 0 45 .19 
1 56.13 ± 19 .11 1 59.47 
4 59.58 ± 16.68 4 73. 76 
18 68.64 ± 22.78 18 68.64 
N.S. 
HDL 0 17 . 91 ± 4.38 0 17.91 
1 16.96 ± 2 . 72 1 17.97 
4 13. 14 ± 6.57 4 16.27 
18 16. 30 ± 8 . 15 18 16. 30 
N.S. 
*Cholesterol values determined enzymatically, represent both free and 
esterified cholesterol 
1Plasma cholesterol values corrected for infusion of Liposyn 
Values given are mean± SEM. Mean values represent all subjects and 
both collection periods . Significance was determined by repeated 
measures of analysis of variance with trend analysis. 
2P va:lue for trials 
3P value for linear trend 
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TABLE 6 
TOTAL PLASMA VALUES* 
Time Calculated Time Computed 1 
Hours mg/dl Hours mg/dl 
Cholesterol 0 53.8 ± 8.8 0 53.80 
1 47 .9 ± 7.7 1 51. 85 
4 58.8 ± 9.3 4 77. 87 
18 67.4 ± 9.5 18 67 .40 
P < .005 2•3 
Triglyceride 0 180.9 ± 17.5 0 180.90 
1 300.3 ± 35.2 1 330.83 
4 519.0 ± 29.3 4 644.12 
18 193.1 ± 29.3 18 193. 10 
p 
.001 2 •4 
Cholesterol 0 133.3 ± 17.2 0 133.30 
Ester 1 129. 7 ± 19.4 1 136.31 
4 113.5 ± 19.1 4 141. 05 
18 132 .2 ± 24.1 18 132.30 
P < .005 2•4 
Phospholipid 0 193.3 ± 29.4 0 193.10 
1 187.1 ± 25.6 1 199. 89 
4 199.9 ± 25.2 4 287.92 
18 195.1 ± 25.2 18 195 .10 
P < .05 2 
P <. 014 
* Total values mathematically derived from TLC and enzymatic analysis. 
1 Plasma values corrected for Liposyn infusion. 
Values given are mean± SEM for all subjects and both collections. 
Significance was determined by repeated measures of analysis of 
variance (ANOVA) with trend analysis; 2 value for trials, 3 value 
for quadratic trend, 4 value for linear trend. 
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TABLE 7 
* LIPID COMPOSITION OF SERUM LIPOPROTEINS 
% 
Time Cholesterol Triglyceride Cholesterol Phospholipid 
PLASMA 
VLDL 
LDL 
HDL 
Hours 
0 
1 
4 
18 
0 
1 
4 
18 
0 
1 
4 
18 
0 
1 
4 
18 
9.75±2.28 
7.25±1.63 
6.91±1.76 
12.24±2. 76 
P<.001 1•2 
P ( . 0053 
9.57±1.93 
7.57±1.71 
6.98±1.79 
12.37±2.8 2 
P <.001 1 •2 
P<.025 3 
10.04±2.55 
8.65±2.43 
9.51±2.68 
12. 78±2 . 83 
P <. 005 l 
NS2 
P <. 0253 
7.68±2.13 
6.99±1.61 
7. 53±1. 89 
9.67±2.67 
P <. 05 l 
NS2,3 
32.92±4.51 
46.26±5.80 
57.16±5.47 
32.63±4. 72 
P <.001 1 •2 
P <. 005 3 
39. 79±6.42 
45.93±9.59 
50.65±13.43 
30.24±6.98 
P ' . 005 l 
NS2 
P<.05 3 
25.69±6 . 0 
32.20±7.13 
31. 96±7. 38 
24.09±4.09 
NSl,2,3 
11.14±2 .4 
18.82±6.6 
24.76±5.73 
14.81±2.35 
P <. 005! 
P( '.ll 
NS 
I . 
Ester 
23.74±4.08 
19.06±4.02 
12 . 52±2.47 
21.52±3.58 
P <-001 1•2 
NS3 
23.18±3.87 
16.46±2.89 
10.57±2.27 
21.47±2. 73 
1 P (. 0012 
P<. 005 
NS3 
31. 60±6. 05 
27.69±6.94 
18.79±3.26 
28. 77±6. 27 
P <'.. 005~ 
p ( .01 
NS3 
37.21± 9.02 
38.15±10.7 
34 . 23±10 . 4 
30.48± 7.4 
NSl,2, 3 
* Percentage of composition estimated by quantitative TLC. 
33.60±4.77 
27.95±5.44 
25.55±4.75 
33.66±4.17 
NSl,2,3 
23.53±2 . 83 
21.67±4.14 
18.39±3.97 
28.39±2.86 
P (. 025 1 
P (. 05 2 
NS3 
35.87±4.18 
32 . 66±6.61 
33.74±4.87 
36.43±4. 31 
NSl,2,3 
44.00±6.05 
36.91±6.32 
33.49±5 . 43 
44.95±4 . 06 
P<.025 1•2 
NS3 
Values given are mean± SEM for all subjects and both collections. 
Significance was determined by repeated measures of analysis of variance 
(ANOVA) with trend analysis ; 1, value for trials; 2, value for 
quadratic trend; 3, value for linear trend. 
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TABLE 8 
LIPID COMPOSITION OF SERUM LIPOPROTEINS 
CORRECTED FOR PLASMA DILUTION 
mg/dl 
Time Cholesterol Triglyceride Cholesterol Phospholipid 
Hours Ester 
VLDL 0 27.48 114. 31 66.59 67 .60 
1 23. 90 145.01 51.97 68.42 
4 43.63 316.60 66.07 114. 95 
18 31.69 77.47 55.00 72. 73 
LDL 0 15. 73 40.25 49.51 56.20 
1 19. 32 71.92 61. 85 72. 95 
4 33.91 113. 93 66.98 120. 27 
18 29.39 55.40 66.16 83. 78 
HDL 0 4.61 6.69 22. 34 26.41 
1 4.23 11. 39 23.09 20.52 
4 4.39 14 .43 19.96 19.52 
18 5.67 8.68 17.87 26.36 
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Figure 20. Changes in the computed cholesterol values (mg/dl) for plasma lipoproteins corrected 
for plasma dilution (see Table 5) following Liposyn infusion. 
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Figure 21. Changes in plasma lip i d componets (computed mg/dl) corrected for plasma dilution 
(see Tables 6 & 7) following Liposyn infusion. 
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dilution (see Table 8) following Liposyn infusion. 
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dilution (see Table 8) following Liposyn infusion. 
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dilution (Table 8) following Liposyn infusion. 
DISCIBSION 
Since the early 1960's, Intralipid, a phospholipid-
triglyceride emulsion, has been used successfully in a:xnbination 
with dextrose and amino acids to intravenously nourish patients. '!be 
ablility of the l:xrly to rretaoolize intravenous fat emulsions without 
any apparent ill effects has lead the rredical rornnunity to use it 
as a standard rrethod to deliver needed calories and essential fatty 
acids to the debilitated patient. Several questions need to be 
addressed regarding the use of fat emulsions, ncmely: What happens 
to the triglyceride and phosIX1olipid cx:mponents of the emulsions? 
How are they rretaoolized by the l:xrly? What effect cbes the infusion 
have on the l:xrly's lip::>proteins? Over the years, researchers have 
established several rrechanisms and suggested others. 
Nll'lerous sttrlies have indicated that fat emulsions have the 
sarre biological properties as naturally occuring chylanicrons. 
Chylanicrons with their triglyceride load pass into the lacteals of 
the intestinal villi and are transp::>rted by the lymph vessels to the 
thoracic duct. 'lb:>rough a series of enzymatic reactions the 
triglyceride enters the blood stream and is carried to the liver and 
adip::>se tissues for rretaoolism and storage. After eating a rich 
fatty rreal, a tenporary hyperlipidemia occurs. 'Ibis too is the case 
following an intravenous fat emulsion infusion. 
Hallberg (1965) investigated the clearance of toth fat 
emulsions and chylanicrons by injecting O • 3 granv'kilogram l:xrly 
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weight/two minutes of each solution into d::>gs. T.irred blocxl samples 
were drawn and the clearance rates detennined. ~ fat emulsion 
cleared in a manner and at a similar kinetic rate as the 
chylcmicrons. 
A kinetic principle was developed establishing that elimination 
of the fat emulsion is maximal alx>ve a critical rncentration. 
Below this ooncentration, the elimination is exponential. In man, 
an exarrple of maximal elimination is the indiviooal who has fasted 
overnight and clears 0.16 gram triglyceride/kilogram/hour. If the 
individual oontinues to starve for another 14 hours (39 oours total) 
the clearance rate is increased to 0.24 gram triglyceride/ 
kilogram/hour. By adding an additional stress of al:xbninal surgery 
to a fasted patient, the elimination rate increases to 0.54 gram 
trigylceride/kilogram/hour. Kinney ( 19 80) detennined the clearance 
rate of fat emulsion for traurra and surgical patients. Fbllowing an 
overnight fast, nonnal subjects cleared fat at the rate of 0.219 gm 
tg/kg/hr; traurra patients at 0.242 gm tg/kg/hr; and surgical 
patients at 0.244 gm tg/kg/hr. 
MacFayden and associates (1973) dem:>nstrated a maximum 
triglyceride level following a four oour infusion of 500 ml 10% 
Intralipid in their surgical patients. Within two oours {X)St 
infusion, the triglyceride levels returned to preinfusion values. 
This has been sui:p:,rted by the work of Wihoore (1973) and Fbrbes 
(1965). M:>st recently, Jeejeebooy denonstrated a similiar clearance 
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rate for Intralipid and Liposyn (1979). 
In this stooy, as shown in Tables 6 & 7 and Figures 6 & 8, the 
plasma triglyceride levels peaked at hour 4. By the second hour 
post infusion (hour 6), the annunt of triglyceride in the plasma had 
dropped by 54%. The next rroming, the fat emulsion had cleared and 
the triglyceride values were back to preinfusion levels, indicating 
the pa.tients ablity to handle the fat load. 
'As rrentioned in the Results, these nutritionally depleted 
subjects cleared the fat emulsion at approximately 0.244 gm 
tg/kg/hour. '!his o:mpares to 0.24gm tg/kg/hour clearance rate 
obtained by Hallberg (1965) for individuals fasting 39 hours as well 
as for traurra and surgical pa.tients observed by Kinney (1980). '!his 
is particularly interesting as these sttrly pa.tients had not 
recieved any recent traurra and were not fasting. 'Ibey were being 
fed a nutrient solution optimal in terms of calories, protein, 
vitamins and minerals. 'Ibey were awaiting surgery and were 
oonsidered llEdically stable. Why was the clearance of the fat 
emulsion so rapid? 
A possible answer lies with the 'WOrk of Elwyn and associates 
(1980) who investigated the influence of total pa.renteral nutrition 
on fuel utilization in seµsis and injury in a population of protein 
calorie depleted pa.tients requiring 'IPN. In this study, t'WO diets 
were given; one oontained gluoose as the sole source of non-protein 
energy, while the other isocalorically Sl..1D3tituted Liposyn 10% for 
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one third of the gluoose calories. The resting energy expenditure 
(REE) for each patient was detennined at the start of the stooy as a 
basis for calculation of dietary intake. (REE is the nean daily 
value obtained by rreasurerent of oxygen/ carbon dioxide gas exchange 
at rest. '!his value inclooes the specific dynamic action of food.) 
After each patient had adapted to his/her diet, the am::mnt of 
oxygen oonsurred and caroon dioxide exhaled was rreasured to determine 
the Respiratory QI.Dtient (R.Q.). (R.Q.= rroles caroon dioxide divided 
by rroles oyxgen. The R.Q. varies when carbohydrate, fat and protein 
are oxidized due to the a:xnpositional differences in food stuffs 
which in turn detennine the arrrnmt of oxygen required for cxxnplete 
oxidation and oonsequently the vollll'IE of carbon dioxide given off. 
The cx:xnbustion of carbohydrate requires an equal arrount of rrolecular 
oxygen since the arrount of rrolecular oxygen required for the 
cx:xnbustion of carbohydrates is equal to the arrount of carbon dioxide 
produced. The R. Q. is 1.0. As fat requires rrore oxygen for 
cxxnrustion because the fat rrolecule oontains a low ratio of oxygen 
to carbon and hydrogen, the R.Q. is 0.70). 
When the fat oontaining diet was given, the R.Q. was lower than 
the R.Q. for the carbohydrate diet. The authors oonclooe that under 
oonditions of their stooy that the infusing fat emulsion inrrediately 
increased the rate of fatty acid rretab::>lism with a decrease rate of 
glucose oxidation and an increase rate of glycogen deposition. 
Kinney (1980) using the same research design as Elwyn, 
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suggested that the protein calorie depleted patient when given 
hypertonic glUCX>se-amino acid solutions oonverts the excess glucose 
to fat as evidenced by a R.Q. increasing from O. 83 to 1.05. 
Both Elwyn and Kinney suggest that the stressed t:x:xiy prefers 
fat as a substrate while gluoose is utilized for the central nervous 
sytem, white blood cells, red blood cells and the renal rredulla. 
This may explain the apparently rapid clearance of the fat emulsions 
in this study. 
An inital look at the data suggests that the subjects' 
lip::>proteins experienced little o::xnpositional change (other than 
triglycerides) in resp::>nse to the fat emulsions (Figures 9 through 
19 , Tables 5 through 7) • 'Ihe plasma free cholesterol increased 
slightly (8.5%) while the level of cholesterol ester decreased. 
Plasma phospholipid levels increased by a neager 3. 4%. 'Ihe levels 
of triglyceride increased significantly in VIDL, IDL, and HDL while 
the phospholipid and cholesterol (esterified and free) values 
decreased. 'Ihe literature has suggested that plasma triglyceride, 
free cholesterol and phospholipid levels would increase, with the 
greatest increases occuring in the IDL fraction, creating a 
lip::>protein-X-like particle. 
In a:niparison to the nonnal cholesterol range for this age 
group, these stooy patients had initally low cholesterol values. 
Normal fasting plasma cholesterol for healthy men and 'Wl::freI1 retween 
the ages 55 to 59 is 223 ng cholesterol/dl (Table 9) while in the 
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study :i;:opulation the average is 132.9 reg cholesterol/ell. 'lbese low 
cholesterol values are also seen in I.DL (45.22 reg/ell vs 147.5 reg/ell) 
and HDL (17 .9 reg/ell vs 54 reg/ell). These values are still low when 
~ed to 226. 5 reg cholesterol/ell for nen and \t.Ureil between the 
ages of 50 and 79 who are >10% underweight (Table 10; 
Barclay ,1972). The low dlolesterol values in this stooy may reflect 
diminished fat stores in res:i;:onse to the weight loss experienced by 
the group. 
While the other li:i;:oprotein fractions were depressed, the VIDL 
cholesterol is high in oomparison to nonnal values (Figure 25). The 
elevated values may represent a release of coolesterol from lxrly 
tissues in res:i;:onse to the infused fat emulsion. Barclay (1972) 
re:i;:orted that VIDL levels as much as tripled following a diet of 85% 
carbohydrate and <l % fat for seven days. While these stooy :patients 
recieved only 70% carbohydrate and 30% protein in the fonn of TPN 
for a minimum of five days before the first fat emulsion, it may 
have been enough tirce to create the increase observed. 
'As these :patients are significantly underweight for height 
(Table l; 107 U:s for height of 5' 3"), and plasma volme is directly 
related to lxrly weight ( 43 ml plasma/kg) , it was believed that the 
addition of 500 ml fluid over four oours "WOuld effect their 
hydration state and dilute the plasma values. 'l'b detennine if is 
was so, oorrection factors were derived for these subjects based on 
their rrean kilogram weight (48.9 kg), their inital average plasma 
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volUITe, and the addition of 500 ml fluid. 'Ibese oorrection factors 
were applied to the group rreans for hours 1 and 4 and were refX)rted 
for total lifX)protein cholesterol values (Table 5), total plasma 
values (Table 6), and lipid a:mposition of serum lifX)proteins (Table 
7) • With a oorrection made for dil uti ton of the samples, the data 
took on characteristics refX)rted in the literature (Tables 5, 6, and 
8). '1be plasma triglyceride and phospholipid increased along with 
the levels of free and esterified cholesterol. Triglyceride, 
phospholipid and cholesterl (free and esterified) levels increased 
in toth VIDL and IDL. FIDL oontinued to show an increase in 
triglyceride levels wth a decrease in phospholipid and cholesterol 
(free and esterified) values. 
All lipid cxxnponents increased in the oorrected IDL values 
(Table 8) with the largest increases reing in triglyceride and 
phospholipid. Nurrerous researchers using Intralipid in man and 
animals have sh:Jwn that either alone (Ttxxnpson et al, 1975 & 1976; 
Srepherd et al, 1980) or with total parenteral nutrition (Miyahara 
et al, 19 79 ) , there is an increase in free cholesterol, Iix>spholipid 
and triglyceride. '1be majority of these increases appear in the IDL 
fraction. Due to the high levels of \IDesterified cholesterol and 
phospholipid, reserachers have identified this IDL particle to re 
similar to lifX)protein-X which is seen in bilary obstructive 
disease. 'lb investigate this issue, 'lb:nlpson & associates (1975 & 
1976) infused Intralipid 10% into normal realthy vollIDteers. '!his 
caused a significant rise in the IDL fraction. When an aliqoot of 
-87-
this fraction was visualized under the electron rnicrosoope, round 
particles -were present. On closer examination, these particles 
appeared to be similar to those observed for phospholipid in 
Intralipid. Tt"Ey prop:>se that the egg yolk lecithin in Intralipid 
exchanged with nonnal LDL, increasing the oleate with a reciprocal 
decrease in the linoleate rontent. TtE phospholipid exchange 
resulted in a m:>dification of the fatty acid a::tlp)Sition of lx>th 
lecithin and cholesterol ester of the recipients' plasma 
lip:>proteins. '1be effect was associated with an increase in the 
oleate:linolate ratio of lx>th lecithin and cholesterol ronstituents 
of LDL. The changes in this ratio influence the fractional rate of 
catal:X>lism of apo LDL by altering the ronversion rate of LDL 
cholesterol ester to bile acids. 'Ibis observation was ronfinred by 
Breckenridge and rolleagues (1979). 
After rorrection for dilution, the levels of free cholestrol 
and phos!Xlolipid -were elevated enough in the IDL fraction to suggest 
the presence of lip:>protein-X-like suretance. '1be free cholesterol 
levels may be elevated due to a transfer of the cholesterol fran HDL 
to VIDL to LDL (Figure 25). '1be large increase in triglyceride and 
phospholipid values as -well as the "milky" appearance of this IDL 
fraction up::m separation, suggest the presence of the Lip:>syn 
particle. As suggested by 'llarpson (1976) and Breckenridge (1979) 
in their work with Intralipid, a similar iretal:X>lic event may have 
occurred with Lip:>syn. (Ccmposition of Lip:>syn and Intralipid is 
identical except for the triglyceride source; safflo-wer oil in the 
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case of Li[X)Syn and soybean oil for Intralipid.) The phospholipid 
of Lip:,syn may have exchanged with the subjects' LDL, allowing the 
Lip:,syn particle to float in the LDL density range. However, the 
resp:,nse in this sttrly may not have been as strong as rep::,rted by 
Th::xtpson. Safflower oil has a higher percentage of linoleic acid so 
that the oleate:linolate ratio of the IDL may not have been greatly 
altered. This issue needs to re investigated further. 
Current research suggests that when the triglyceride is rem:>ved 
£ran the chylanicron, the surface of the chylanicron shrinks (Tall & 
Small, 1978). The redundant surface constituents of phospholipid, 
free cholesterol and ap:,proteins A and C fonn lipid bilayer folds 
projecting £ran the chylanicron. Disklike particles or vesicles can 
re forrred £ran these cxxnponents. Bilayers can fonn £ran the 
chylanicrons creating unstable bilayered sheets. These sheets seal 
to fonn vesicles. Circulating spherical HDL may interact with these 
vesicles a,nating apo A-I. If apo A-I is present, the particle 
tecares a good sul:strate for lecithin: coolesterol acyltransferase 
( IJ:AT) • '!his enzyrre causes the transfer of a fatty acid rroiety fran 
the 2 p:,sition of lecithin to unesterified cholesterol, fonning 
cholesterol ester and lysolecithin. The hydropoobic cholesterol 
ester particle rroves into the center of the disccrlial HDL fonning a 
sphere. The lysolecithin is rem:>ved by binding with alb..mri.n in 
plasma or converted to glycerylphosphorylcooline (Glanset, 1979). 
The apo A-I depleted HDL has lost a large part of its surface and is 
now unstable and may fuse with other lip::,proteins. If this fusion 
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occurs with the chylomicron, cholesterol ester oould re transported 
back to the liver in the remant. 
The lipids in lipoproteins are associated with proteins through 
hydrophobic oonds • Glarset ( 19 70 & 19 79) suggest that during 
oollisions arrong lipoproteins and plasma rrembranes, these oonds 
(especially those involving free cholesterol) are reversible 
disrupted. '!he surface lipids re~ individual lipoproteins and 
lipoproteins and plasma rrembranes (erythrocytes) can exchange. 
Nichols and oolleagues ( 19 65) dem:mstrated that in the presence 
of I.CAT, :EIDL cholesterol esters oo transfer to VIDL; this transfer 
is accanpanied by a back transfer of VIDL triglyceride to the IIDL. 
It is thought that the cholesterol esters fonred by I.CAT rest on the 
surface of the IIDL rrolecule and these esters transfer rrore easily 
than those that have underc;pne rearrangement within the IIDL 
particles. 
!Dth VIDL and IIDL are secreted directly into plasma. Due to 
the action of lipoprotein lipase, the VIDL innediately regins to 
lose triglyceride to the peripheral tissues. 'Ihese changes oonvert 
VIDL to IDL. '!he LDL oontinues to change by the I.CAT induced 
nonenzymatic transfer of unesterified cholesterol and lecithin and 
in addition, reacts directly with I.CAT. 'Ibis reaction causes a slow 
rise in IDL coolesterol ester, derived partly fran the transfer of 
:EIDL coolesterol ester to VIDL and frcm the direct attact of I.CAT on 
IDL. 'Ihe coolesterol ester cea::ires the predaninant lipid in IDL. 
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Nascent HDL oontain little cholesterol and very little, if any, 
cholesterol ester. 'As they circulate, they lose lecithin by 
reacting with I.CAT. '!be lecithin is partially replenished by net 
transfers fran VIDL and LDL. '!be tmesterified cholesterol is also 
lost as the HDL particle circulates, however it is nore a:xtl)letely 
replenished fran net transfer of VIDL, IDL, and plasma rrenbranes. 
It has been recognized that the cholesterol ester transfers 
am:mg the li:i:x>proteins (Glosmet, 1979). Rehnl::org and Nicools (1964) 
daronstrated that hunan HDL cholesterol exchanges with VIDL 
triglyceride and this is praroted by the ICAT reaction. 
Subjects with a ICAT deficiency have altered native VIDL and 
LDL. '!be VIDL are present in al::normally high ooncentrations and 
oontain al::out half the normal anount of cholesterol ester. '!be VIDL 
also oontains al::nonnally high oontent of apoprotein C-I and a:i:x> E 
relative to a:i:x> C-II, C-III, and B. In plasma are particles of the 
sane size and appearance as normal LDL b.lt which oontain al::nonnally 
large anounts of triglyceride in cx:inparision to cholesterol ester. 
·Aoother larger LDL particle resemble li:i:x>protein-X (IP-X); an 
al:normal circulating li:i:x>protein carrying an tmsually high 
pro:i:x>rtion of phospholipid and cholesterol ester (Glosmet,1979). 
Norum and associates ( 19 75) incubated hunan plasma fran 
patients with I.CAT deficiency with the enzyire. Both VIDL and IDL 
-were markedly altered. A major decrease in the lecithin and 
tmesterified cholesterol oontent in the large LDL occurred as did an 
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increase in coolesterol ester in the VIDL and normal sized IDL. 
Ap.:>protein E transfered fran HDL to the VIDL; apoprotein C 
transferred fran VIDL to HDL. It appears that the large sized LDL 
contributes lecithin and unesterified coolesterol to HDL. '!he 
action of !£AT converts these su.tstrates to cholesterol ester and 
lysolecithin. The newly forrred coolesterol esters transfer fran HDL 
to normal sized LDL and VIDL in association with ap.::,protein E. ~ 
D is the transfer protein. '!he lip.:>proteins in HDL seen to provide 
the reactive surface utnn which !£AT can act to fonn cholesterol 
ester. 'lhe "forrred" dlolesterol ester can then transfer to other 
lip.:>proteins. Ctolesterol esters remaining in the HDL appear to 
have increased the affinity of these lip.:>proteins for ap.:>protein A-I 
and to prarote the exchange of apoprotein E fran HDL with C 
apoproteins fran VIDL (Glanset,1979). The nechanisrt5 underlying 
these transfer reactions have not yet been oonclusively established. 
It is knc,r,,.n that rat lymph chylanicrons when transp.:>rted to 
the plasma, undergo major changes in apoproteins whereby a 
characteristic ap.::,protein pattern is established (Havel, 1973). 
Ap.:>protein E and D are acquired; ap.::, A is lost to HDL while a back 
transfer &:mates apo C peptides to the chylanicron. 'lhese acquired 
apoproteins probably dictate the ITEtal:x:>lic fate of the chylanicron 
in the system. 
To detennine if a similar exchange occurs on the fat emulsion 
-92-
particle, Robinson and Quardfordt ( 19 79 ) incubated Intralipid with 
rat and hurran plasma and examined it for changes in the lipid and 
apoprotein CXllp)Sition. Uµ>n incubation in rat plasma, Intralipid 
acquired an ap::>protein a:xnplercent similar to that found on 
chylcmicrons incubated in plasma. Ap:>protein A and E joined on, 
while incubation of Intralipid in hurran plasma showed the uptake of 
Ap:> A-I and Ap:> A-N as well. When the plasma was separated into 
the various lip::>proteins classes, it was note that high density 
lip::>protein is the major ap::>protein oonor to Intralipid. 
These results suggest that Intralipid and chylanicrons 
sul::sequently undergo similar rretaoolic fates. The presence of ap::> 
C-II on the fat anulsion particle may activate the extrahepatic 
lip::>protein lipases to bring al::x::mt lip::>lysis of roughly 90% of the 
triglyceride within the particle. '!he triglyceride is hydrolyzed to 
free fatty acid and glycerol. '!he fat anulsion particle is now, 
probably, a rennant containing al:x::>ut 10% of its original 
triglyceride nolecules. Due to the high ap::> E a:mtent of the 
particle, the rennant may be cleared by the liver (Sherill,1980) and 
its canponents used to fonn VIDL ( Glanset, 19 79 ) • '!he degree to 
which this may have occurred is questional as these subjects are 
malnourished (Table 1). This factor along with a low total protein 
and alt:..nnin levels (Table 2) would indicate decreased protein 
synthesis in the liver. 'Ibis diminished protein production may have 
limited ap::>protein synthesis, making the acquistion of ap::>proteins 
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difficult. 
"As VIDL is secreted and produced from the liver, it is highly 
tmlikely that synthesis a:mld account for the elevation in 
phospholipid and triglyceride observed here (Table 8). As the 
lip::>protein separation technique used did not separate the VIDL 
fraction from the infused fat emulsion, there is a strong 
p::>ssibility that this VIDL fraction is oontaminated by the fat 
emulsion. However, the increase in cholesterol and cholesterol 
ester rrore than likely is a real phenarenon as neither lipid was 
infused. 
In this study, when oorrected for plasma dilution, an increase 
in cholesterol, triglyceride, cholesterol ester, and phosph:::>lipid in 
VIDL occurred as expected. An increase in cholesterol, 
triglyceride, cholester ester, and phospholipid in LDL was seen. 
Tha HDL fraction showed an increase in triglyceride CXX1current with 
a decrease in toth cholesterol ester, and phospholipid. '!his sttrly 
assurred that the fat emulsion cleared in a manner similar to that of 
natural chylcxnicrons, i.e. hydrolysis of the fat particle by 
lip::>protein lipase. As the triglyceride is reroved, the surface 
~nents bud out fonning bilayers and acquire ap::> A-I and bea::ne 
substrates for I.CAT. Accx:>rding to Marcell (1973) when HDL is 
pre-incuba.ted with Intralipid, the I.CAT reaction is stimulated and 
thereby increases cholesterol ester synthesis. "As noted in this 
sttrly tx:>wever, cholesterol ester falls in HDL. 
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Quardfordt ( 19 71 ) ol:served an increase in cholesterol ester in 
VI.DL and an associated increase in triglyceride in the HDL following 
an incubation of human plasma at 37 C in Intralipid. 'lliis ma.y be due 
to the action of cholesterol ester transfer protein which transfers 
cholesterol ester £ran HDL to VIDL and/or IDL: while it is 
"associated with a reciprocal and equim::>lar back trans:EXJrt of 
triglyceride £ran VI.DL and IDL to HDL" (Chajek, 1978: Figure 25). 
Nestel (1979) observed that rate of cholesterol ester-HDL reroval is 
equivalent to the rate of HDL cholesterol esterified. '!he VIDL and 
chylanicrons may be cleared by liver and provide a trans:EXJrt 
irechanism of cholesterol ester to the liver where it is excreted 
through the bilary system. 
In sunmary, it is believed that in these :patients the fat 
emulsion :particle is iretal:x:>lized in a manner similar to the 
naturally occuring chylanicrons, by acquiring an ap:>protein 
CXlI!plerrent. 'lliis protein profile allows for interaction with 
lipoprotein lipase for the catal:x:>lism of triglyceride as well as 
interaction with ICAT to allow for the formation of esterified 
cholesterol ( Figure 25 ) • '!he response to ICAT may not have been as 
great as expected due to the protein depleted state of the sttrly 
population. '!he low total protein and alblmin levels would indicate 
diminshed protein synthesis by the liver. 'lliis in turn would 
suggest that apoprotein synthesis may be depressed. '1he low alblmin 
levels would also imply that there is little alblmin to bind with 
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lysolecithin ferried as a by-product of the I.CM' reaction. This may 
have resulted in a negative feedback to prevent the maxiumun 
cholesterol ester formation. 
Another !X)Ssiblity for the results lies in an observation made 
by Kinney and Elwyn ( 19 80 ) • In their prospective studies, protein 
depleted patients -were observed to nEtal:x>lize the infused fat 
anulsion as a primary energy source. This would leave little fat 
anulsion available to take part in the rretabolic pathway offered 
earlier. 'Ihese factors may explain the reasons for the results 
obtained in this thesis st'lrly. Future research projects can address 
these questions. 
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TABLE 9 
Total Plasma Cholesterol (mg/dl) and Cholesterol (mg/dl) 
Distribution Among Plasma Lipoproteins of 
Fasting Normal Subjects (Heiss etal, 1980) 
Total Plasma 
Cholesterol VLDL LDL 
F M I COMBO F M COMBO F M COMBO 
I 
231 215 I 223 21 22 21. 5 150 145 147. 5 
i 
I 
132.9 ± 12 67.1 ± 20.8 45.2 ± 23.5 
HDL 
F M 
60 48 
45.2 
COMBO 
54 
± 23. 5 
I 
\0 
O' 
I 
TABLE 10 
Cholesterol Levels in 248 Normal Subjects (Barclay,1972) 
<10% Underweight 0-10% Underweight 0-10% Overweight 
VLDL. 90.5 117 .5 139 
TOTAL 
CHOLESTEROL 226.5 242.5 252 
> 10% Overweight 
133 
252 
I 
ID 
-.J 
I 
Apo A-I, 
C,E 
Free fatty acid Triglyceri~ 
""'Glycerol 
& . I D C,~~ Ap~ -
PL 
Figure 25 
POSSIBLE SCHEME OF FAT E/.f/LsroN METAJlOLISM 
Hepatic 
Receptor Sites 
TG = Triglyceride 
CE= Cholesterol Ester 
C = Free Cholesterol 
PL= Phospholipid 
I 
\0 
0:, 
I 
SI~IFICANCE 
It has been theorized that if a diet rich in p:,lyunsaturated 
fats was given to a p:,pulation, it would decrease plasma cholesterol 
and increase the level of HDL cholesterol. Epidaniological stooies 
over the past several years have shown that there is a very strong 
negative correlation between plasma HDL cholesterol levels and the 
probability of developing coronary heart disease (Barr et al, 1951; 
Miller & Miller, 1975; Gorden et al 1977; Castelli et al, 1977). 
Barr, Russ and Elder (1951) were one of the first to identify 
changes in HDL and IDL levels in coronary heart disease ( CHD) • '!hey 
stooied protein-lipid relationships in atherosclerosis in patients 
with clinical evidence of CHD. Fran their ohservations, they 
conclooed that "the outstanding (feature) is the relative and 
atsolute reduction of alpha (equivalent to HDL) lip:,proteins in 
atherosclerosis" with a "relative and atsolute increase in beta 
(equivalent to IDL) lip:,proteins. '1hese changes were ohserved 
without hypercholesterolemia or significant increase in the 
cholesterol-rnospholipid ratio. 'Ihese results were confirnro over 
twenty years later by Castelli and associates in the Cooperative 
Lipoprotein Phenotyping Stooy (1977) and the Framingham Heart Study 
(Gordon et al, 1977). 
The Cooperative Lipoprotein Phenotyping stooy examined five 
population group; throughout the United States; over 6,800 nen and 
~ over the age of 40 years were inclooed. It was found that the 
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nean HDL cholesterol level was lower in individuals with roronary 
heart disease than those without the disease. '!be significant 
difference in HDL levels between the groups was only three to four 
mg/dl (P<.01; Castelli et al, 1977). 
The Framingham Heart Study reviewed 2,800 nen and 'WCIIefl between 
the ages of 49 and 82 years. 'Ibey roncltrled that the increased HDL 
cholesterol level appeared to have the strongest relationship with 
the decreased incidence of roronary heart disease (P<.001) in either 
nen or ~. '!he total cholesterol level in this group was not 
associated with an increased risk of roronary heart disease (Gordon 
et al, 1977). 
Miller and Miller have offered a ITEChanism whereby the 
decreased plasma HDL cholesterol levels may impair nonnal clearance 
of cholesteral fran arterial walls and therby increase the 
developnent of atherosclerosis. '!hey suggest that roronary heart 
disease may be prevented by increasing plasma HDL concentration and 
hence clear cholesterol fran arterial walls rather than attanpt to 
manipulate plasma cholesterol levels (Miller & Miller, 1975). 
The epidemiological evidence that slx>ws a negative rorrelation 
between HDL cholesterol and the prevalence of the incidence of 
ooronary heart disease is strong. 'Ibis gives one the tendency to 
place too much weight on the value of HDL levels. Further research 
must be cbne before we can make definite ronclusions regarding the 
role of HDL. However, in the case of LDL, we have not only 
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epidemiological evidence but additional research sttrlies that 
definitely implicate LDL as having a direct causative role in 
atherogensis (McGill, 1979). 
Atherosclerosis can be produced in experimental animals 
( incltrling non-hurran primates) by increasing the I.DL level. 
Patients with extremely high I.DL levels (:patients with h:xrozgotes 
familial hypercholesterolemia) have an accelerated progression of 
atherosclerosis. 'lbese :patients often have myocardial infarcts by 
age ten or fifteen (Brown & Goldstein, 1975, 1976, 1979); while 
:patients with an amence of HDL (Patients with Tangiers disease) 
have no clear evidence of premature atherosclerosis (McGill, 1976). 
Several dietary intervention trials have slx>wn reduction in LDL 
levels. While no dietary sttrlies have dem::>nstrated an elevation of 
HDL, low cholesteol, low saturated fat diets have been slx>wn to 
lower t:oth I.DL and IIDL levels ( Spepherd et al , 19 78 , 19 80 ) • 
\'brk by Brown and Goldstein (1975, 1976, 1979) implies that I.DL 
:participates directy in atherogensis by penetrating into the artery 
wall and delivering rrost of the cholesterol that accumulates in the 
tissues. 
The atherosclerotic lesion can occur in all major arteries of 
the t:ody. '1be lesion is an accrnmlation of lipid, rrostly 
cholesterol derived fran IDL which results in a :partial or corrplete 
block of the lrnen of an affected vessel. '!he overall effect is an 
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interference with the flow of arterial blood to vital organs. 'llle 
symptans that result may affect the central nervous system, the 
heart, the intestines, the kidney, and the extremities (Mc-Gill, 
1976). 
HDL may slow the atherogenic process by facilitating reverse 
cholesterol trans:i;:ort fran cells of the artery and restrict cellular 
cholesterol by inhibiting the uptake of IDL by the cells of the 
artery walls • 
As discussed earlier, HDL is an excellant li:i;:oprotein sul::strate 
for ICAT ( Glanset, 19 70) • This enzyire forrrs cholesterol ester f ran 
cholesterol and lecithin on the surface of the HDL bilayer. 'llle 
cholesterol ester enters the discodial HDL fonning a sphere while 
lysolecithin is rerroved by plasma alb.mri.n. 'llle fonnation of surface 
cholesterol to cholesterol ester and its rroverrent into the particle 
oontinues until the available FIDL lecithin is exhausted. 
Part of the circulating FIDL is evidently derived fran 
cataoolism of chylanicrons and VIDL by the en<i:>thial li:i;:oprotein 
lipase (Tall & Sma.11,1978). During chylanicron clearance, there is 
a shift of cholesterol, phospholipid, and protein(~ A,C, and E) 
into HDL (Hanilton,1978). 'Ibis lipid transfer process may involve 
fonnation of new HDL particles fran circulating a:i;:oprotein A-I 
(:p1ospho- lipid exxtplex) and fran degraded VIDL and chylanicrons. 
During TPN, the infusion of a fat emulsion is functioning in a 
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manner sbnilar to that of a natural chylanicron in that it picks up 
an a:i::oprotein oomplex to allow for catal:x>lism of its triglyceride 
oore. Since the fat emulsion is an excellent phospholipid source, a 
transfer of the phospholipid fran the fat and its recently acquired 
apoproteins (artifical chylanicron) to HDL ma.y occur. A HDL 
particle rich in phospholipid is fanned ( HDL precursor) • '!his 
disa::>dial HDL OOCCIIES a sutstrate for ICAT and thereby oould 
aa:ruire free cholesterol fran the plasma and trans:i::ort cholesterol 
as cholesterol ester to the liver for catal:x>lism. In this way, the 
infusion of a fat emulsion may be an effective irethod of increasing 
circulating HDL and in turn be used as a irethod for the treat::lrent of 
atherosclerosis in man. 
Initally it was thought that an artifical chylanicron oould be 
used to stimulate I.CAT to allow for eventual clearance of 
cholesterol ester which in turn may clear plaques f ran artery walls. 
Over a period of time following infusion of the fat emulsion, the 
increase in the levels of HDL phospholipid and cholesterol ester 
\\10uld indicate that this event was taking place. To accanplish this 
and to minimize gastrointestional secretions, patients with 
cx:mpranised GI system=; were used to investigate them. 'Ibis 
approach, however, proved to be very simplistic as the patient 
population not only had non-ftmctional guts but were also 
malnourished as a result of their disease. 'lbe question of protein 
calorie malnutrition was not initally oonsidered to be a factor, 
however the final results of the stooy indicate this was a major 
ooncern. 'lbree possible avenues of exploration have becare evident. 
First, to investigate the effect of the fat emulsion infusion on 
normal, healthy individuals to determine if a::np::>nents of the fat 
emulsion oontrirute to the formation of discoidal HDL particles, 
thereby oontrirute to the treatment of atherosclerosis. Secondly, 
to stooy the effect in the rredically stressed patient of 
protein-calorie malnutrition oo plasma lipoproteins, by ~s of 
identifing the "oormal" levels of lipoproteins and their 
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subfractions. 'lbirdly, to investigate in this s~ JX)pulation if 
the fat anulsion is indeed used as a prinnary energy source as 
outlined by Kinnery and Elwyn. 'Ihese areas oould present intriguing 
research ideas for the near future. 
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I, --:-:----------,----,,----~-' give 1'l!{ cx:nsent to having my blood 
drawn "'1hile I am recieving total parenteral. nutritim ('IPN) whidl is 
a rea:>glized rreans of providing rre w.ith nutritimal suwcrt while 
I am being treated for my disease. 
'11,e p\JilX>5e of the blcod tests will l:e to determine the changes 
in cholesterol and triglyreride levels of my blood while I am 
recieving 'JPN and a 10% fat emulsicn solution. 
A small indwelling p:,lyethylene catheter will be placed in a 
peripherial vein in my ann before the fat enillsion is given. 'Ihe 
placerrent of the catheter neans that I will not have to be stuck 
repeatedly with a needle to draw blood sarcples. 'Ihe cath:ter will 
be used so blood sarcples my be taken before, during, and follcwing 
the infusion of the fat soluticn. A maxinum of 50 ml ( 1 1/2 ounce) 
of blood will be taken in a 24 hour period. The blood sarcples will 
be used to determine the distributim of the fat em.ilsion into ey 
tissues as well as to note the dlanges in ch:>lesterol and triglyceride 
levels of my blood. 'Ihis procedure will be repeated twice. 
'!his study will help further identify the effect of fat m the 
lx>dy' s cholesterol and triglyreride levels. 'Ihere will be no direct 
benefit to myself fran participaticn in this study. 
All infonnation cbtained fran this study is confidential, My 
privacy will be protected at all tirces. 
I understand that all my questicns regarding this stl.Xly will 
be answered before I sign this cx:nsent fonn. If I decide not to 
participate in this study or to wi thdra,,., fran it, it will not in any 
wey affect the quality of my rredical care. I may withdraw fran this 
study at any tine I desire. 
I understand that in the event i:nysical injucy occurs resulting 
fran the research procedures, Iredical treabTent will be available 
at University Hospital. lbwever, no special arrangenents will be 
rrade for cx:mpensaticn or for payrrent for treabrent soley because of 
It¥ participation in this ~irrent. I understand that this paragraph 
is a statenent of University Hospital's p:,licy and does not .waive 
any of 11¥ legal rights. 
,M. D. , has eJ<plained this stl.Xly to rce, He 
---------------has answered all of my questicns and has inforrred rce of the disrornforts 
and risk of having my blood drawn. 
Volunteer's signature Date 
Witness Witness 
t] 
DESCIIPTION 
T1-lE, IV 
HIGH 
ENERGY 
SCURCE 
l1posyn 10%, !Intravenous Fat Emulsion} is a 
sterile, nonpyrogemc fat emulsion prepared 
tor Intr1venous 1dmmistrat1on Uposyn 10'°,'o 
contains 10% safflower oil, 1.2°10 egg phos• 
phatides and 2.5% glycerin in Water for ln1ec-
hon Sodium hydroxide has been added to ad• 
just the pH 10 approximately 8.0. 
The safflower oil is a mixture of neutral tr i-
gtycendes of predominantly unsaturated flny 
acids. The fatty acids forming the major com-
ponent of the emutsion are IK'loleic (77% ), 
oleic 113%). palmitic (7%1 and stearic acid 
12.5'1o) 
l.Jposyn 10% has an osmollrny of approiu-
mately 300 mOsm/hter and contains emul-
sified fat particles of approJtimately 0.4 micron 
in diameter, similar to naturally occumng 
chyiomicrons. The total caloric value of Lipo-
syn 10% including fat, phospholipid and 
glycerol is 1.1 kcal/ml Of this total, 0.675 
kcal/ml ,s supplied by linole1c acid 
ACTIONS 
Liposyn 100.4 provides the patient requiring 
parenteral nutrition with a source of calories 
and the essential fatty acids normally obtained 
from a nutritionally complete oral diet. The 
supplemental polyunsaturated hit prevents 
biochenwt:al changes of essential fatty acid de-
ficiency IEFAO) and prevents and reverses 
EFAO clinical manifestations (scaliness of skin, 
growth retardation. poor wound healing, 
sparse hair growth!. 
The infused fat particles are cleared from 
the bloodstream in a manner thought to be 
simiiar to the clearing of chytomicrons. 
IIIDICATIONS 
Liposyn 10% is indicated as a source of 
calories for patients requiring parenteral nutri-
tK>n. Where such nutrition is required for ex-
tended periods of time (more than 5 days). 
Liposyn 100/o 1s also indttated as a source of 
essential fatty acids to prevent biochemical 
changes In fatty acid composition of plasma 
lipids leleY1ted 1riene/tetr11ne notio) -,d the 
clinical manifestations of EFAD. 
CDNTIWNIHCAT10NS 
The admm1st ration of L.iposyn ""- IS amtrwin· 
dicated in premature tntents with a bilirubin of 
more than 5 mg/100 ml or in patients dem-
onstrat ing distu rbances in normal fat 
metabolism such as pathologic hyper~pemia. 
Wpoid nephrosis or acute p,ncr11trtis if ac-
companied by hyperlipemia. 
This stable emulsion should not be mixed 
with electrotytes, nutr~nts or other additive 
solutions. However, heparin has been shown 
to be stable when added to the emulsion at • 
concentration of 1 to 2 units per ml. Fihers 
should not be used for administration of the 
emulsion 
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Liposyn"· 10% 
INTRAVENOUS "4T EMULSION 
Liposyn 10% is supplied in single-dose con-
tainers. PaniaHy used bottles must be dis• 
carded and should not be stored or re-
sterilized for later use. Do not administer the 
contents of any container in which the emul· 
sion appears to be oiling out. 
MIIMNGS 
Caution should be exercised in administering 
Liposyn 10% to patients with severe lfVer 
damage, pulmonary disease, anemia or bkJod 
coagulation disorders or when there is danger 
of fat embolism. 
,wfCAUTIONS 
During Liposyn 10°/o therapy, the patient's 
hemogram, blood coagulation, liver function. 
platelet count and plasma ltptd profile must be 
closefy monitored. The hpemia must clear be· 
tween daify infusions 
Liposyn 10°/o should be discontinued should 
a significant abnormahty in any one of these 
parameters be attributed to the therapy 
ADmsE IIEACTIONS 
Sepsis due to contamination of administration 
equipment and thrombophlebit,s due to vem 
irritation from cortcurrently administered 
hyperton,c solutions have been encountered. 
These are anributable to I.V. therapy in gen-
eral or to the type of 1nfusion administered. 
Adverse reactions directly related to fat 
emulsions are of two types: (1) immediate 
lacute) and 121 long-term (chronic). In studies 
of lipid products in general, the followmg im-
mediate reactions have been noted: Allergic 
reactions. hyper1ipemia. dyspnea, cy1nosis, 
flushing, diuiness , headache, sleepmess, 
nausea, vomiting, hyperthermia. sweating, 
chest and back pain, thrombocytopema (rarely 
in neonates), hypercoaguiability and transient 
increases in liver eniymes 
The following reactions hive been noted 
with long-term therapy with lipid infusions 1n 
general: Htpatomegaly, jaundice due to cen-
tnol lobular cholestasis. spienomegaly, throm-
bocytopenia, ltucopenil . transient increases 
in ~ver function tests, DYlr1oading syndrome 
-,d the deposition of brown pigment rfat 
pigment") in the reticulotndothelial tissue of 
the hver. The stgnificance of this last occur-
rence and rts cause are unknown. 
DOSAGE ANO ADMM11S111A7JON 
Liposyn 10¾ !Intravenous Fat Emulsion) 
should be administered as part of an intrave-
nous total nutritiort program via peripheral 
win or central vtnous catheter. 
M,,tt,--
Liposyn 10% can provide up tc 60% of doily 
calories 11 1 dose not to uceed 3 g/kg of 
body weight per cloy. The other 40% si'ould be 
provided by carbohydnote and 1milo ICids 
11-2m10-1m 
For the prevention of essential tany acid 
deficiency, the recommended daily require-
ment ,s 1pprox1m1tefy 4% of the caloric intake 
as linoleate. In most adult patients, this can be 
supplied as !iOO ml of Liposyn 10% admin,s-
tored twice weekly. 
The infusion should be started at a rate of 
1.0 ml/minute for the first lS mmutes. If no 
adverse effects are observed during this in1t1al 
infusion, the rate can be increned to allow no 
more than 500 ml to be given over a period of 
four to six hours. 
l'9dialric:"--
Liposyn 10% can provide up to 60o/, of daily 
calories at a dose not to exceed 4 g/kg of 
body weight per day. The other 40't, should be 
provided by carbohydr1te and amino acids. 
F-or the prevention of essential fatty acid 
deficiency, the recommended daily require-
ment is approximately 4% of the caloric intake 
as linoleate The daily dosage ranges tram 5 ml 
to 10 ml per kilogram. depending upon the size 
and maturity of the patient. 
The mfusion should be started at a rate of 
0.1 ml/minute for the first 15 minutes If no 
1dverse effects are observed during this initial 
infusion, the rate can be increased to allow no 
more than 100 ml per hour. 
Ado!ioillnltion 
See CONTRAINDICATIONS regarding mixing 
this emuts10n with other I.V. flutds or add•· 
tfVes. Liposyn 10o/o can be infused mto the 
same cent ral or peripheral vein as the 
carbohydrate/amino acid soluttOns by means 
of a short Y-connector near the intusk>n site. 
This allows for mixing of the solutions im-
mediatefy before entanng the vein or for al-
ternation of each solution. Flow rates of each 
solution should be controlled sepanotely b in-
fusion pumps, if these are used. Fat emulsion 
moy also be infused through • sepanote 
periphenol site. If dosirad, heparin moy be 
added to Liposyn 10% 11 1 concentnotion of 1 
to 2 units per ml prior to 1dministr1tKJn. 
l.ipilkontlining fluids hove I propensity to 
extnoct phthelates from phthelate-plasticized 
polyvinyl chloride IPVC). Although the amount 
is very small and no adverse cUnical effects 
hive been reparted from administration of 
111c:h lfflOUnts of phthelate, it may be 1dvisa-
tM1 to consider administration of Liposyn 10% 
through • non-phthelate infusion set. 
S71111AGE 
Protect from freezing. Do not store above 
30° C (86' Fl. 
HOWs,,,tJB/ 
Liposyn lO'lo ~List No 43351 is supplied in !iOO 
ml and 200 ml stngl~ ose containers. 
Clution: Fodenol lUSA/ '- prohibits dispens-
i,,v without 1"91Cription. 
97-33'1 ·25-1/79 EJ Abbott Laboratories, North Chicago, IL 60064, USA PRINTED IN U.S.A 
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